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ABSTRACT 
 
 
 
Tumor progression is a multistep process in which cancer cells perform an 
intricate cross-talk with their surrounding stromal environment, generating a 
bidirectional communication that affects tumor survival, proliferation and 
aggressiveness. Among several cell types that constitute the tumor stroma, 
mesenchymal stem cells (MSCs) selectively migrate toward tumor 
microenvironment and contribute to the active formation of tumor-associated 
stroma, thus promoting cell survival, angiogenesis, invasion, evasion of 
immune system and metastasis.  
In this thesis, I investigated the role of bone marrow-derived MSCs (BM-
MSCs) in tumor processes, deepening the involvement of specific signaling 
pathways underlying their recruitment and activity into tumor 
microenvironment. In particular, innovative therapeutic tools have been tested 
to: 1) inhibit BM-MSC-mediated growth and aggressiveness of osteosarcoma 
(OS) and hepatocellular carcinoma (HCC) cell lines by targeting CXCR4; 2) 
interfere with BM-MSC recruitment by triple negative breast cancer (TNBC) 
cells through modulation of PDGFRβ signaling. 
For the first purpose, I tested a new CXCR4 inhibitor, Peptide R, which was 
recently developed as an anticancer agent to overcome the toxicity of the well-
known CXCR4 antagonist AMD3100. I observed a reduction in BM-MSC-
mediated OS and HCC migration and invasion and a parallel decrease in BM-
MSC-dependent phosphorylation of ERK and AKT. Furthermore, Peptide R, 
targeting and inhibiting CXCR4, prevented Epithelial Mesenchymal Transition 
(EMT) of OS and HCC cells promoted by BM-MSCs.  
For the second purpose, I used a novel aptamer-based PDGFRβ inhibitor, 
named Gint4.T. Aptamers, thanks to their unique characteristics (low size, 
good target affinity, no immunogenicity, high stability), represent a new class 
of molecules with a great potential to rival monoclonal antibodies in both 
therapy and diagnosis. I observed that Gint4.T, binding PDGFRβ, inhibited the 
phosphorylation of the receptor and its downstream signaling significantly 
preventing in vitro BM-MSC cell migration and blocking cell proliferation. 
Finally, I found that Gint4.T strongly reduced in vitro BM-MSC migration 
stimulated by two different Triple Negative Breast Cancer (TNBC) cell lines, 
suggesting that it could interfere with BM-MSC recruitment and their pro-
tumorigenic activity within breast cancer microenvironment. 
Therefore, this study represents an initial development of novel tumor 
microenvironment-targeting therapies that, in combination with conventional 
approaches-oriented to tumor cells, may offer more effective alternative to treat 
cancer patients by targeting BM-MSCs. 
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1. BACKGROUND 
 
 
 
1.1 Cancer 
 
 
Cancer is an intricate multistep process involving genetic and epigenetic 
alterations that result in the activation of oncogenic signals and/or inactivation 
of tumor suppressor pathways.  
During cancer progression, cancer cells acquire a number of hallmarks that 
ensure their survival and proliferation and, therefore, tumor growth.  
The ability of a cancer cell to undergo migration and invasion allow it to 
invade the surrounding stroma, enter the circulation and eventually metastasize 
to distant organs.  
However, tumor growth involves tumor cells themselves, but also other cells, 
tissues, and molecules in the environment surrounding the tumor, the tumor 
microenvironment (TME). A tumor can influence its microenvironment by 
releasing extracellular signals, by promoting tumor angiogenesis and inducing 
the inflammatory response, whereas the stroma cells in the microenvironment 
can sustain tumor growth and promote metastasis development (Quail and 
Joyce 2013).  
For this purpose, multi-targeted approaches, for both tumor cells and tumor 
microenvironment and/or the signaling pathways involved in their 
communication, may offer a more efficient way to treat cancer. 
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1.2 Tumor microenvironment 
 
 
Cancer is not merely a mass of malignant cells, but a complex system to 
which many other cells are recruited and can be corrupted by the transformed 
cells. Interactions between malignant and non-transformed cells create the 
tumor microenvironment.  In particular, interactions between tumor cells and 
the associated stroma generate a bidirectional communication that affects 
disease, beginning and progression, and patient prognosis (Hanahan and 
Coussens 2012). 
The stroma consist of a class of cells, including fibroblasts/myofibroblasts, 
glial, epithelial, fat, immune, vascular, smooth muscle, and immune cells along 
with the extracellular matrix (ECM) and extracellular molecules. Though none 
of these cells is naturally malignant, they acquire an abnormal phenotype and 
altered functions due to the environment, interactions with each other, and 
directly or indirectly cross-talk with cancer cells.  
The concomitant participation of various stromal components, including 
immune/inflammatory cells, carcinoma associated fibroblasts (CAFs), cancer 
stem cells (CSCs), as well as the activation of processes in which these factors 
are strongly involved (hypoxia, angiogenesis, epithelial-mesenchymal 
transition and metastasis), results in tumor microenvironment formation and 
progression (Hanahan and Coussens 2012) (Figure 1). 
In particular, among several cell types, that constitute the tumor stroma, 
mesenchymal stem cells (MSCs) have been shown to selectively migrate 
toward tumor microenvironment and promote cancer progression and 
metastasis by supporting tumor stroma activity (Barcellos-de-Souza et al. 
2013).  
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Figure 1. The primary tumor microenvironment. Cancer cells in primary tumor are 
surrounded by a complex microenvironment including multiple stromal cell types that 
converge to promote tumor growth and dormancy, invasion and metastasis 
development and resistance to therapy. 
 
 
 
1.2.1 TME: Immune-mediated dormancy 
 
 
The role played by the immune system in regulating tumor growth and 
propagation is crucial. Most of the immune cell populations in the tumor 
microenvironment interplay to prevent (or promote) the local growth of tumors 
and their spread:  
 in the immune-suppressive microenvironment context, natural killer 
(NK) cells represent key cytotoxic tumoricidal lymphocytes, but also 
regulatory cells engaged in reciprocal interactions with dendritic cells, 
macrophages, T cells and endothelial cells (Vivier et al. 2008); 
 dendritic cells (DCs) are the major antigen processing and presenting 
cells in the tumor milieu and usually act as the link between the innate 
and the adaptive immune systems (Banchereau and Steinman 1998); 
 macrophages, often referred to as tumor associated macrophages 
(TAMs), interact with a wide range of growth factors, cytokines and 
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chemokines, which are thought to determine TAM functional role as 
tumoricidal/static (M1 polarization) or tumor promoters (M2 
polarization) (Biswas and Mantovani 2010); 
 myeloid-derived-suppressor cells (MDSCs) are a heterogeneous 
population of immune cells from the myeloid lineage that infiltrate the 
growing tumor and perform strong immunosuppressive activities 
(Talmadge and Gabrilovich 2013); 
 the TH (T Helper) population, bearing CD3+ and CD4+ markers, 
performs a dual function, based on the subsets and the ratio of their 
populations. TH1 cells mediate a tumor suppressor inflammatory 
reaction, whereas TH2 can mediate a tumor promoter reaction 
(Coussens et al. 2013); 
 B-lymphocytes mediating humoral immunity can promote cancer 
progression by altering the TH1/TH2 ratio to favor tumorigenesis (de 
Visser et al. 2005);  
 cytotoxic T lymphocytes, bearing the CD8+ marker, can identify and 
destroy cancer cells through their major histocompatibility complex 
(MHC) recognition when recruited to the tumor milieu (Fridman et al. 
2012); 
 regulatory T cells (T regs) are crucial for peripheral tolerance as they 
maintain the homeostasis of innate cytotoxic lymphocytes, regulating 
the expansion and activation of T and B cells. They are intimately 
involved in immunological diseases and cancer (Zeng and Chi 2013). 
The various components of the immune system seem to interplay with the 
stromal factors, regulating tumor growth and dissemination. It seems evident, 
therefore, that immune modulation should be a crucial component in the fight 
against cancer. The presence of suppressive factors in the tumor 
microenvironment, however, may explain the limited activity observed with 
previous immune-based anti-cancer therapies and why these therapies may be 
more effective in combination with agents that target immune modulators of 
the tumor microenvironment. Emerging clinical data suggest that cancer 
immunotherapy is likely to become a key part of the clinical management of 
cancer.  
 
 
 
1.2.2 TME: Cancer Associated Fibroblasts (CAFs) 
 
 
A specialized group of fibroblasts, named cancer associated fibroblasts 
(CAFs), is one of the most crucial components of the tumor microenvironment, 
which promotes the growth and invasion of cancer cells. 
Compared to normal fibroblasts, CAFs are constantly activated, neither 
reverting back to a normal phenotype nor undergoing apoptosis. CAFs found in 
different cancers are highly heterogeneous, and they are potentially derived 
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from resident fibroblasts through genetic alterations, but also from epithelia, 
endothelia or mesenchymal cells (Xing et al. 2010). 
In particular, recent evidence has suggested that MSCs selectively proliferate 
in tumor microenvironment and contribute to CAF formation (Mishra et al. 
2008). 
Several CAFs markers were identified including alpha-smooth muscle actin 
(alpha-SMA), fibroblast activation protein (FAP), desmin, and vimentin.  
Alpha-SMA has been known to play an essential role in the embryonic stem 
cell-derived cardiomyocyte differentiation. However, the expression of alpha-
SMA in the tumor stroma increases fibroblast contractile ability and 
contributes to alterations in cytoskeletal organization (Rønnov-Jessen and 
Petersen 1996). Conversely, fibroblast activation protein (FAP) expression is 
not detected in normal fibroblasts, but its expression has been associated with 
an overall poorer prognosis in several cancer types, including colon, ovarian, 
pancreatic, and hepatocellular carcinoma (Brennen et al. 2012). 
For this reason, it is becoming clear that the crosstalk between tumor stromal 
cells and CAFs plays a key role in the progression of cancer, and understanding 
this mutual relationship would eventually offer a novel way to treat cancer 
patients by targeting CAFs. 
 
 
 
1.2.3 TME: Hypoxia and angiogenesis 
 
 
Hypoxia is a concomitant microenvironmental factor, considered as a 
negative prognostic indicator associated with a significantly increased risk of 
metastasis and mortality in many human cancers (Kim et al. 2009). 
Intratumoral hypoxia contributes to cancer progression affecting the behavior 
of both cancer and stromal cells. The effects of hypoxia on cancer cells can be 
essentially classified in: (1) shift to a glycolytic metabolism to circumvent lack 
of oxygen, (2) activation of pathways for survival to stressful conditions, (3) 
stimulation of de novo angiogenesis allowing nutrient/oxygen supply, (4) 
activation of Epithelial Mesenchymal Transition (EMT) program to escape 
from the hostile environment (Wilson and Hay 2011). 
In addition, hypoxia strongly influences also stromal cells, essentially affecting 
the profibrogenic/proangiogenic behavior of CAFs (Giaccia and Schipani 
2010). 
Hypoxia-induced signaling is primarily mediated by the ubiquitous hypoxia-
inducible factor-1 (HIF-1), a master regulator of O2 homeostasis that consists 
of two subunits, HIF-1α and HIF-1β, sensitive or insensitive to O2 
modification, respectively. HIF-1-induced genes are involved in a wide range 
of cellular functions such as cell growth, survival, motility, angiogenesis, 
energy metabolism, and cellular differentiation (Ziello et al. 2007).  
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Several studies have demonstrated that angiogenesis, which is necessary for 
tumor progression, is influenced by the tumor microenvironment. Angiogenesis 
is the physiological process through which new blood vessels form from pre-
existing vessels. However, angiogenesis performs a crucial role in development 
of cancer. To spread, solid tumors need to be supplied by blood vessels that 
bring oxygen and nutrients and remove metabolic wastes. In fact, oxygen and 
nutrients have difficulty diffusing to the cells in the center of the tumor, 
causing a state of cellular hypoxia that marks the onset of tumoral angiogenesis 
(Nishida et al. 2006). In this scenario, hypoxic tumor microenvironment has 
emerged as a primary physiological regulator of the angiogenic switch 
activating the transcription of various factors, including vascular endothelial 
growth factor (VEGF), angiopoietin 2, and fibroblast growth factor 2 (FGF2) 
(Semenza 2013). In addition, there is abundant evidence that stromal cells in 
the TME are instrumental in switching on and sustaining chronic angiogenesis 
in many tumor types. CAFs, for example, through chemokine secretion, 
promote angiogenesis by recruiting endothelial progenitor cells (EPCs) into 
carcinomas (Orimo et al. 2005). Importantly, also MSCs seems to be involved 
in the formation of new blood vessels. For instance, Suzuki et al. 2011 have 
demonstrated that combined administration of MSCs and tumor cells promoted 
tumor growth by enhancing angiogenesis in syngeneic tumor models. This 
enhanced neovascularization can likely be attributed to direct support of 
neovascularization by MSCs and to secretion of angiogenic factors, including 
VEGF and others, by MSCs. 
 
 
 
1.2.4 TME: EMT and metastasis development  
 
 
One of the main features of tumor milieu is the ability to elicit a clear escape 
adaptive strategy for cancer cells, called epithelial mesenchymal transition. 
EMT is an epigenetic program in which epithelial cells lose their cell polarity 
and cell–cell adhesion, undergo cytoskeleton reorganization, and gain 
morphological and functional characteristics of mesenchymal cells. EMT is 
essential for numerous developmental processes including mesoderm 
formation and neural tube formation. However, it has been shown that EMT 
occurs also in wound healing, in organ fibrosis and in metastasis initiation of 
cancer progression (Thiery et al. 2009). 
EMT is a regulated process in which the cell loses its epithelial markers and 
achieves expression of mesenchymal markers. A property of EMT is the loss of 
E-cadherin expression, correlated with tumor grade and stage (Giannoni et al. 
2012).  
Cadherins mediate calcium-dependent cell-cell adhesion and play critical roles 
in normal tissue development. E-cadherin is considered an active suppressor of 
invasion and growth of many epithelial cancers. Recent studies indicate that 
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cancer cells have up-regulated N-cadherin in addition to loss of E-cadherin, 
causing the “cadherin switch” (Aigner et al. 2007). 
Vimentin is an intermediate filament of mesenchymal origin and is present at 
early developmental stages. Vimentin is a clear marker of mesenchymal 
phenotype and its up-regulation concurs with the loss of E-cadherin expression 
(Kokkinos et al. 2007).  
Others several transcription factors have been implicated in the control of 
EMT, including Snai1, Slug, Twist, zinc finger E-box binding homeobox-1 and 
-2 (ZEB1 and ZEB2) (Cannito et al. 2010).  
Initiation of metastasis requires invasion, which is supported by EMT. 
Carcinoma cells in primary tumor lose cell-cell adhesion mediated by E-
cadherin repression, break through the basement membrane with increased 
invasive properties, and enter the bloodstream through intravasation. Later, 
when these circulating tumor cells exit the bloodstream to form 
micrometastases, they undergo Mesenchymal Epithelial Transition (MET) for 
clonal outgrowth at these metastatic sites. Thus, EMT and MET form the 
initiation and completion of the invasion-metastasis cascade (Yao et al. 2011). 
 
 
 
1.2.5 TME: Cancer stem cells (CSCs) 
 
 
Stem cells, as classically defined, are cells with the ability to perform 
asymmetric cell divisions. Each cell, therefore, can self-renew in one that is 
identical to it, as well as generate a different one, in that it is more committed 
towards a certain differentiation pattern. (Cariati and Purushotham 2008). 
In contrast to the ‘stochastic’ model of oncogenesis, where transformation 
results from random mutations and subsequent clonal selection, experimental 
and clinical data have accumulated to support the hypothesis that cancer may 
arise from mutations in stem cell populations (Cancer Stem Cell Hypothesis). 
Indeed, Cancer Stem Cells (CSCs) result involved in the pathologic 
manifestation of cancer affecting tumor initiation and metastatic progression, 
and increasing resistance of tumors to conventional cancer therapies (Reya et 
al. 2001). 
Some functional environments, namely ‘cancer stem cell niches’, may support 
CSCs. CSC niches provide a unique microenvironment where CSCs interact 
closely with tumor stromal cells. Their maintenance, therefore, is subjected to 
regulation by microenvironmental signals, including cytokines, vascular 
effects, and modulation of immune responses. In this context, CSCs niche 
plays a crucial role in keeping CSCs in a quiescent stage leading them to 
preferentially survive tumor therapy, and persists long term to ultimately cause 
delayed cancer recurrence and metastatic progression (Kleffel and Schatton 
2013). 
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1.2.6 TME: Mesenchymal stem cells (MSCs)  
 
 
Mesenchymal stem cells are non-hematopoietic multipotent stromal cells 
widely distributed in a variety of adult tissues, including bone marrow, the 
umbilical cord, Wharton's Jelly, adipose tissue, peripheral blood, placenta and 
lung (Barcellos-de-Souza et al. 2013).  
In such tissues, MSCs are either constantly present or their pool is replenished 
by the migration of bone marrow-derived MSCs (BM-MSCs) (Bergfeld and 
DeClerck 2010), thus representing the latter the most intriguing class of MSCs. 
Normally, MSCs are recruited into sites of injury and inflammation and 
differentiate into a variety of connective tissue cell types such as bone, 
cartilage, muscles, tendons and adipose tissue (Dominici et al. 2006). 
Once at injury site, it has been widely reported that MSCs possess broad 
immunoregulatory capabilities by which they are capable to influence both 
adaptive and innate immune responses. In fact, MSCs can suppress immune 
responses by producing immunomodulatory molecules including tumor growth 
factor β (TGF-β) and nitric oxide, as well as, stimulating potent 
immunosuppressors as CD4+ or CD8+ regulatory T cells (Burr et al. 2013). 
Furthermore, MSCs have been showed to suppress the activity of a wide range 
of immune cells, including natural killer cells, dendritic cells, B cells, 
neutrophils, monocytes and macrophages (Zhao et al. 2010). 
However, several studies have also reported that MSCs are rapidly recruited 
into tumor microenvironment in response to a variety of endo/paracrine signals 
that attracts them directly in a receptor-mediated manner (Korkaya et al. 2011). 
In particular, due to their remarkable ability to home to tumor sites and their 
immune privileged status, BM-MSCs have been used as carriers for delivering 
anti-tumor agents to the tumor microenvironment (Barcellos-de-Souza et al. 
2012).  
Nevertheless, BM-MSCs have a dual function. In fact, they have also been 
identified as pro-active tumor stroma associated cells that are implicated in 
promoting cell survival, angiogenesis, invasion, and metastasis,  as reported in 
breast (Chaturvedi et al. 2013), lung (Suzuki et al. 2011), prostate (Jung et. al 
2013), and colon (Shinagawa et al. 2010) carcinomas (Figure 2). 
Within the tumor microenvironment, tumor-associated BM-MSCs increase the 
population of cancer stem cells (CSCs) with a high metastaticity, dormancy 
and chemoresistance (Liu et al. 2011 and Luo et al. 2014).  
Importantly, BM-MSCs can differentiate into cancer-associated fibroblasts 
(CAFs), promoting EMT phenomenon required for establishing distant 
metastasis (Jung et al. 2013).  
To date, the molecular mechanisms underlying these processes have remained 
elusive.  
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Figure 2. Bone marrow-derived mesenchymal stem cells (BM-MSCs) support 
tumor progression.  The bidirectional signaling between BM-MSCs and cancer cells 
attracts BM-MSCs in a receptor-mediated manner into tumor sites. BM-MSC 
infiltration into pathogenic microenvironment promotes the malignant transformation 
of proliferating cancer cells to an EMT. EMT promotes the invasion-metastasis 
cascade. 
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1.3 Targeting tumor microenvironment for therapy 
 
 
The key role played by stromal cells in determining or enhancing multiple 
hallmark capabilities in the tumor microenvironment of different types of 
cancer clearly prompts therapeutic targeting strategies aimed to inhibit their 
contributions. One benefit of therapies targeting the microenvironment is that 
these non-tumor cells are more genetically stable than tumor cells and thus are 
less likely to gain adaptive mutations and acquire drug resistance (Dimou et al. 
2012). 
However, a limitation of targeting stromal cells in the tumor microenvironment 
is that a fragile balance exists between their tumor-inhibitory and tumor-
promoting functions (Li et al. 2007). As such, it become very important to 
identify and target key molecular differences between these cells under normal 
tissue homeostasis versus when they are co-opted or altered by the tumor 
microenvironment.  
Recent studies have suggested various approaches to target different cell types 
in the tumor microenvironment (Figure 3). 
As increasing data underline the important role by TAMs during tumorigenesis 
and cancer progression, a variety of pre-clinical studies were also performed to 
test the concept of TAM-based anti-cancer therapy. In 2006, Luo et al. 
presented a DNA vaccine based on legumain, which is over-expressed on 
TAM. The administration of the DNA vaccine in mouse induced a robust 
CD8+ T cell response against TAM. The distribution of TAM in tumor 
microenvironment was reduced and the production and release of pro-
angiogenic factors such as, TGF-β, VEGF and matrix metallopeptidase 9 
(MMP-9) from TAM was inhibited. As a sequence, the growth and metastases 
of a variety of tumors were significantly inhibited. 
For their ability to enhance tumorigenecity, angiogenesis, and metastatic 
dissemination of cancer cells compared with normal fibroblasts, CAFs are 
considered a very attractive candidate for tumor-targeted therapies. For 
example, Loeffler et al. (2006) have shown that the use of DNA vaccines 
directed against fibroblast activation protein (FAP), resulted in the elimination 
of tumor growth, metastasis and recurrence in mouse tumor models.  
Due to their capabilities to home to tumor sites and promote cancer 
progression, MSCs have become a promising target for attenuating the tumor 
malignancy in treating patients. In particular, recent studies have reported that 
the pro-tumorigenic effect of MSCs could be inhibited hampering the cross-
talk between MSCs and tumor cells, and interfering with MSC-derived CAF 
differentiation within tumor microenvironment. Shinagawa et al. (2013), for 
example, have shown that interfering with platelet-derived growth factor 
(PDGF) signaling pathway impairs MSC migration and their tumor-promoting 
effect in an orthotopic colon tumor model. Furthermore, Shangguan et al. 
(2012) have reported that blocking TGF-β/Smad signaling in human BM-
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MSCs prevented their differentiation to CAFs in tumor microenvironments and 
abolished their protumor effects. 
Thus, in this scenario, investigate the involvement of specific signaling 
pathways underlying BM-MSC recruitment and role in tumor 
microenvironment, and develop innovative therapeutic tools to target and 
prevent their activity, may offer a novel way to treat cancer patients by 
targeting BM-MSCs. 
 
 
 
 
 
Figure 3. Tumor microenvironment targeted therapies. The tumor 
microenvironment comprises various cell types that modulate treatment response and 
are putative candidates for therapeutic intervention. Multiple strategies to target the 
tumor microenvironment are either currently in clinical use or are at different stages of 
clinical development. 
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1.4 CXCR4 and cancer 
 
 
Chemokines are a family of small peptides that function as chemoattractant 
cytokines involved in cell activation, differentiation, and trafficking (Balkwill 
2004). 
Chemokines are expressed in discrete anatomical locations and act on 
chemokine receptors (CKRs), members of the seven-transmembrane domain 
G-protein-coupled receptor (GPCR) superfamily (Rajagopal et al. 2010). Most 
chemokines bind to multiple receptors, and the same receptor may bind to 
more than one chemokine. The C-X-C motif chemokine 12 (CXCL12), also 
known as stromal cell-derived factor-1 (SDF-1), for example, binds to CXC 
receptor 4 (CXCR4) (Murdoch 2000) and 7 (CXCR7) (Miao et al. 2007). 
CXCR4 is an evolutionarily highly conserved GPCR expressed on monocytes, 
B cells, and naïve T cells in the peripheral blood. CXCL12 binding to CXCR4 
triggers multiple signal transduction pathways that are able to regulate 
intracellular calcium flux, chemotaxis, transcription, and cell survival. As a G-
protein-coupled receptor, the mechanism of CXCR4 receptor activation is 
mediated by coupling to an intracellular heterotrimeric G-protein associated 
with the inner surface of the plasma membrane. The heterotrimer is composed 
by Gα, Gβ and Gγ subunits, and in its basal state binds the guanosine 
diphosphate (GDP). Upon activation by ligand binding, GDP is released and 
replaced by guanosine triphosphate (GTP), which leads to subunit dissociation 
into a βγ dimer and the α monomer to which the GTP is bound. In turn, 
different subtypes of the α subunit impart different signals: Gαi subunits inhibit 
cyclic adenosine 3',5'-monophosphate (cAMP) formation via inhibition of 
adenylyl cyclase activity, and the Gαq subunits activate phospholipase C (PLC) 
generating diacylglycerol (DAG) and inositol 1,4,5 trisphosphate (IP3), which 
controls the release of intracellular Ca2+. While inhibiting adenilyl cyclase, the 
Gαi subunits activate the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB), janus kinase-signal transducer and activator of 
transcription (JAK-STAT) and phosphatidylinositol-3-kinases-AKT (PI3K-
AKT) pathways as well as, c-Jun N-terminal kinases (JNK)/p38 and mitogen-
activated protein kinases (MAPKs) pathways, thus, regulating cell survival, 
proliferation, and chemotaxis (Teicher and Fricker 2010).  
CXCL12 binding to CXCR4 also causes CXCR4 desensitization in which 
CXCR4 intracellular phosphorylation lead to β-arrestin recruitment and 
subsequent CXCR4 lysosomal degradation (Marchese 2014) (Figure 4).  
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Figure 4.  Pathway signaling of CXCL12-CXCR4 axis. 
 
 
 
CXCR4 is over-expressed in more than 23 different types of human cancers as 
reported in kidney, lung, brain, prostate, breast, pancreas, ovarian and 
melanomas, and is involved in several aspects of tumor progression including 
angiogenesis, metastasis, and survival (Chatterjee et al. 2014). Several studies 
have shown that CXCR4 also contribute to the tumor-stromal interaction. In 
mouse models of human breast (Orimo et al. 2005) and prostate cancer (Olumi 
et al. 1999), high intratumoral CXCL12 levels attract CXCR4-positive 
inflammatory, vascular, and stromal cells into the tumors, where they 
eventually support tumor growth by secreting growth factors, cytokines, 
chemokines, and proangiogenic factors. 
In particular, Orimo et al. (2005) have detected an increased expression of 
CXCR4 in CAFs, suggesting that the transdifferentiation of normal human 
mammary fibroblasts to tumor-promoting CAFs could be induct by CXCR4 
expression. 
Similarly, recent studies have demonstrated that the CXCR4/CXCL12 axis is 
critical for BM-MSC recruitment to tumor sites. As reported by Yu et al. 
(2015), for example, BM-MSCs can promote osteosarcoma cell proliferation 
and invasion in vitro involving the CXCR4/CXCL12 axis. In hepatocellular 
carcinoma, rat BM-MSCs enhance migration in a rat hepatoma cell line 
(CBRH-7919) by up-regulating CXCR4 (Li et al. 2015). Conversely, Li et al. 
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2015 (Eur. J. Med. Res.) showed that BM-MSCs promote proliferation of 
human hepatocellular carcinoma cells, but inhibit their migration. 
As a result of its pleiotropic role in tumor development, the CXCL12/CXCR4 
axis is considered an important potential target for cancer therapeutics. 
Small molecular inhibitors of CXCR4 are being investigated in various disease 
settings. TG-0054 is an injectable small molecule CXCR4 antagonist that is 
currently in phase I/II clinical trials for multiple myeloma, non-Hodgkin 
lymphoma, and Hodgkin disease (Hsu et al. 2015). Another small molecule, 
AMD070, an orally active CXCR4 antagonist, is under clinical investigation 
for the prevention of T-tropic HIV infection (Murakami et al. 2009).  
However, the bicyclam plerixafor (formerly known as AMD3100) represents 
the most effective CXCR4 therapeutic targeting. AMD3100 is a small 
molecule with two cyclam rings connected by a phenylene linker. At 
physiological pH, two nitrogens on each ring are protonated allowing specific 
charge-charge interactions with the carboxylate groups on CXCR4, thus 
inhibiting CXCL12 binding and downstream signaling events (De Clercq 
2009). AMD3100 is approved by the Food and Drug Administration as an 
hematopoietic stem cell mobilizer in patients with non-Hodgkin lymphoma and 
multiple myeloma refractory to conventional protocols for mobilization (Vose 
et al. 2009). Nevertheless, Plerixafor has evoked some concerns regarding its 
cardiotoxicity and other adverse events and it is, therefore, not an ideal 
anticancer agent (Hendrix et al. 2004). 
Thus, there is the urgent need to develop new specific CXCR4-targeting drugs 
to overcome AMD3100 toxicity, and for long-term use as anticancer agents. 
 
 
 
1.4.1 Development of a novel CXCR4 antagonist 
 
 
Recently, in order to develop new CXCR4 antagonists suitable for anticancer 
therapy, Portella et al. (2013), employing a ligand-based approach, conceived a 
new family of peptides to bind CXCR4 and antagonize its activity. 
The analysis of short structural motifs in the ligand receptor-binding region (N-
terminal region) of CXCL12 identified a three-residue segment R-Ar1-Ar2 
(where Ar is an aromatic residue), making this motif a promising candidate 
scaffold to design short CXCR4-ligand peptides. This segment resulted similar 
to, but in reverse order (Ar1-Ar2-R), a peculiar inhibitory chemokine secreted 
by herpes virus 8 known as vMIP-II.  Consequently, two motifs were used as 
templates to design cyclic peptides with the structure C-Ar1-Ar2-R-C and C-R-
Ar1-Ar2-C, where the cysteines at each end in a disulfide-bridge are useful to 
stabilize the structure and provide protection from proteases. In addition, 
peptides were either elongated at their C-termini or, after sequence-reversal, at 
their N-termini, so as to mimic another possibly conserved basic residue motif 
(Italian Patent nu MI2010A000093; International Patent nu WO2011/ 092575 
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A1) (Amodeo et al. 2010). The in vitro evaluation of the CXCR4 inhibitory 
efficacy resulted in the selection of four peptides, named R, S, T and I, that 
showed concomitant antagonistic activity in four in vitro assays (competition 
with anti CXCR4 antibody binding, ligand dependent migration, calcium efflux 
and p-ERK induction). In order to identify the best CXCR4 inhibitor suitable 
for anticancer therapy, peptides R, I, S and T were selected for in vivo 
evaluation. Solubility limitations prevented the evaluation of peptide T in vivo, 
but peptides, R, I and S reduced lung metastases in mice injected with B16-
CXCR4 mouse melanoma cells and K7M2 mouse osteosarcoma cells. In 
addition, peptides R, I and S inhibited primary tumor growth in a xenograft 
model of human renal cancer cells, SN12C. Peptide R especially revealed the 
best efficacy both in in vitro and in vivo analysis and its evaluation for a first in 
human Phase I trial is planned in patients with advanced tumors (Figure 5). 
 
 
 
 
 
Figure 5. Representative structure of Peptide R. 
 
 
 
1.4.2 CXCR4 as therapeutic target for osteosarcoma and hepatocellular 
carcinoma microenvironment 
 
 
Osteosarcoma (OS) is the primary malignant bone tumor that most 
commonly affects children, adolescents and young adults. Specifically, it is an 
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aggressive malignant carcinoma that originates from primitive transformed 
cells of mesenchymal origin (and thus a sarcoma) and that shows osteoblastic 
differentiation and results in malignant osteoid. These tumors are typically 
locally aggressive and favor the development of early systemic metastases. 
More than 85% of metastatic disease occurs in the lung, whereas bone is the 
second most common site of distant disease. The current primary strategy for 
newly diagnosed osteosarcoma consists of neoadjuvant chemotherapy followed 
by surgical removal of the primary tumor as well as all clinically evident 
metastatic disease, plus the addition of adjuvant chemotherapy after surgery. 
As a result, the long-term cure rate for non-metastatic osteosarcoma following 
surgery has risen from 25 to 60%. However, despite these progresses, the 
survival rate for patients with osteosarcoma remains low, with novel effective 
therapeutic strategies required to target this disease (Luetke et al. 2014).  
To date, molecular therapy for osteosarcoma patients has not been developed 
yet. Over past years, several studies have shown the involvement of the 
CXCR4/CXCL12 axis in the occurrence and metastatic potential of OS, 
suggesting that CXCR4 could be promising therapeutic target for the treatment 
of osteosarcoma patients (Lu et al. 2015; Perissinotto et al. 2005). 
Importantly, recent evidence has demonstrated the involvement of tumor 
stroma cells in promoting osteosarcoma aggressiveness through the 
CXCR4/CXCL12 axis (Yu et al. 2015), indicating the possibility to target 
CXCR4 in order to interfere with the cross-talk between osteosarcoma 
microenvironment and tumor cells.  
Hepatocellular carcinoma (HCC) is the fifth most common form of cancer 
worldwide and the third most common cause of cancer-related deaths. HCC is 
often secondary to either a viral hepatitis infection (hepatitis B or C) or 
cirrhosis.  Surgical resection is currently considered the most curative strategy, 
but in the last decade highly satisfactory outcomes have been achieved with 
systemic targeted therapies focus on the critical steps of the carcinogenic 
pathways. To date, for patients with advanced HCC, sorafenib is the only 
approved therapy, but novel targeted agents and their combinations are 
developing (Raza and Sood 2014). 
Recent evidence has shown that the role of the microenvironment in tumor 
initiation and progression in HCC is critical. The interaction between stromal 
and tumor cells is dynamic and dramatically modifies the behavior and 
aggressiveness of HCC. Recent studies, for example, have underlined the role 
of inflammatory pathways in the development of HCC in cirrhotic patients, 
suggesting the possibility to reprogram the immune microenvironment in 
tumors to improve the efficacy of standard anticancer treatments (Hernandez-
Gea et al. 2013). 
Importantly, in 2015 Li et al. have demonstrated that conditioned medium from 
rat BM-MSCs enhance migration of a rat hepatoma cell line (CBRH-7919) by 
up-regulating CXCR4. This evidence suggests the importance of investigating 
the role of BM-MSCs in HCC microenvironment, and how their interactions 
with cancer cells could be modulate targeting critical tumorigenic pathways.  
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1.5 PDGFRβ and cancer 
 
 
PDGFs are a family of potent mitogens for most mesenchyme-derived cells. 
The PDGF family consists of four polypeptides, A-D, forming five disulfide-
linked dimeric proteins: PDGF-AA, -BB, -AB, -CC, and -DD, that signal 
through two structurally similar receptor tyrosine kinases (RTKs), PDGF 
receptors α and β (PDGFRα and PDGFRβ) (Fredriksson et al. 2004). Ligands 
and receptors can form homodimers or heterodimers depending on cell type, 
receptor expression, and ligand availability. PDGF-BB and PDGF-DD are the 
primary activators of ββ homodimeric receptors. PDGF-AA activates only αα 
receptor dimers, whereas PDGF-AB, PDGF-BB, and PDGF-CC activate αα 
and αβ receptor dimers (Yarden et al. 1986). The dimeric ligand molecules 
bind to two receptor proteins simultaneously and stimulate receptor 
dimerization, autophosphorylation of specific residues within the receptor's 
cytoplasmic domain, and intracellular signaling (Figure 6). PDGFRβ signaling 
pathway activation induces several cellular processes, including cell 
proliferation, migration and angiogenesis (Cao et al. 2004; Ostman 2004).  
 
 
 
 
 
Figure 6. PDGF receptor family and their ligands. 
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Pathogenic roles of altered PDGFRβ signaling have been determined for a 
number of human diseases including cancer. Preclinical studies have shown an 
important role for the overexpression, point mutations, deletions, and 
translocations of PDGFRβ in tumorigenesis and maintenance of the malignant 
phenotype (Gilbertson and Clifford 2003), but have also proven that the 
targeted inhibition of PDGFRβ signaling pathway has significant anticancer 
effects (Kilic et al. 2000).  
Recently, MSCs have been reported to express abundant PDGFRβ that plays a 
crucial role in specifying MSC commitment to mesenchymal lineages (Ng et 
al. 2008). Furthermore, PDGFRβ signaling has also emerged as a predominant 
pathway in recruitment of BM-MSCs towards tumor sites (Veevers-Lowe et al. 
2011), contributing to enhance the aggressive and invasive properties of a 
several types of cancer, including chronic lymphocytic leukemia (CLL) (Ding 
et al. 2010), pancreatic (Beckermann et al. 2008), and colon (Shinagawa et al. 
2013) carcinomas. 
Therefore, due to its crucial role in tumor progression, PDGFRβ represents a 
valuable target for tumor therapeutic development.  
To date, several tyrosine kinase inhibitors (TKIs) that act on a wide spectrum 
of tyrosine protein kinases including PDGFRβ are under development as 
anticancer agents. 
Among them, Imatinib mesylate (Gleevec®/STI571) was developed as TKI by 
inhibiting fusion proteins breakpoint cluster region-Abelson Tyrosine-Protein 
Kinase (Bcr-Abl) in chronic myeloid leukemia (Druker et al. 2001). However, 
it has been demonstrated that imatinib has clinical efficacy also in 
gastrointestinal stromal tumors by inhibiting c-Kit (Dagher et al. 2002), and in 
the treatment of a variety of dermatological diseases (Akhmetshina et al. 2009; 
Spiera et al. 2011). Many studies and clinical trials to assess its effectiveness in 
PDGFRβ-expressing cancers are being performed (Cristofanilli et al. 2008; 
Maass et al. 2014; Wen et al. 2006). 
Furthermore, Shinagawa et al. (2013) have reported that imatinib therapy 
impairs the tumor-promoting effect of BM-MSCs in an orthotopic 
transplantation model of colon cancer, suggesting that PDGFRβ inhibition 
could prevent BM-MSC recruitment to tumor microenvironment. 
Sunitinib malate (Sutent®/SU11248) is a broad-spectrum, orally available 
multitargeted TKI with activity against VEGFR, PDGFR, c-Kit, and FMS-like 
tyrosine kinase 3 (FLT-3).  In several phase I/II/III studies, sunitinib was found 
to be effective as second and first line treatment in metastatic renal cell 
carcinoma (RCC). In fact, with a 37% response rate and an additional 48% 
stable disease, sunitinib became the drug of choice for first line treatment in 
RCC (Polyzos et al. 2008). In patients with gastrointestinal stromal tumors, 
sunitinib results also effective as second line treatment with 8% response rate, 
70% stable disease and a 20-month median survival (Pilotte 2015). A phase II 
clinical trial in multi-treated women with breast cancer demonstrated that 
sunitinib has a moderate activity with 16% clinical benefit (Fratto et al. 2011). 
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Sorafenib (Nexavar®) is an inhibitor of Mitogen-activated protein kinases 
(MAPKs) pathway and of angiogenic receptor tyrosine kinases (RTKs) 
VEGFR2 and PDGFRβ. Concerning PDGFRβ targeting blockage, it has been 
shown that sorafenib inhibits oncogenic PDGFRβ and overcome resistance to 
other TKi (Guida et al. 2007; Lierman et al. 2007). Several clinical trials have 
been performed to test sorafenib efficacy specially in treatment of advanced 
hepatocellular carcinoma (Keating and Santoro 2009; Ogasawara et al. 2016), 
and in metastatic thyroid cancer (Ferrari et al. 2015). 
These TKIs might overcome molecular heterogeneity within or between cancer 
patients and, therefore, have a better chance of success; however, unnecessary 
targeting of multiple receptors could cause toxicity and limit drug effectiveness 
(Dancey and Chen 2006).  
Neutralizing antibodies for PDGF ligands and receptors have been used in 
experiments evaluating the importance of PDGF signaling in pathogenic 
processes but, to date, none of such antibodies has entered the clinic (Shen et 
al. 2009). 
Thus, there is the urgent need to design new PDGFRβ-targeting drugs for a 
more specific and selective tumor therapy. 
 
 
 
1.5.1 Targeting PDGFRβ: Gint4.T aptamer 
 
 
Aptamers are short single-stranded nucleic acid oligomers (ssDNA or RNA) 
with a specific and complex three-dimensional shape able to bind to a wide 
variety of targets from single molecules to complex target mixtures or whole 
organisms (Hermann and Patel 2000) (Figure 7A).  
Unlike other small noncoding RNAs either natural or artificial, such as 
antisense, ribozymes, small interfering RNAs (siRNAs) and microRNAs 
(miRNAs) that inhibit gene expression, aptamers act by directly binding the 
protein target without interfering with its expression (Cerchia and de Franciscis 
2006) (Figure 7B). 
DNA or RNA aptamers are isolated from large pools of different 
oligonucleotides by an in vitro evolution-based approach named Systematic 
Evolution of Ligands by EXponential enrichment (SELEX). This process starts 
with a DNA library obtained from combinatorial chemical synthesis. The 
library usually consists of a random region of 20–80 nucleotides flanked by 
fixed 5’ and 3’regions necessary for polymerase chain reaction (PCR) 
amplification and a promoter sequence for T7 RNA polymerase. Aptamers are 
selected, amplified by RT-PCR and then reselected at higher stringency with 
the process repeated as needed to achieve the desired affinity and specificity 
for the target. After cloning and sequencing, selected aptamer sequences can be 
synthesized and tested for their ability to bind specifically to the target 
molecule (Ellington et al. 1990). 
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Aptamers have a small size (8-15 kDa) which permits easy membrane 
penetration and short blood residence and can be chemically modified to 
improve their stability, bioavailability, and pharmacokinetic. In fact, aptamers 
generated by SELEX process, especially RNAs, are unstable in biological 
fluids. To protect RNA from digestion by nucleases, chemically modified 
nucleotides are incorporated into the oligonucleotide backbone. The most 
commonly employed functional group modifications are 2’-F, OMe, or NH2 
modifications of the nucleotides, all of which can be introduced at either the 
pre- or post-SELEX step (Keefe and Cload 2008).  
 
 
 
 
 
Figure 7. Aptamer functionality. A) Schematic representation of aptamer three- 
dimensional structure and functionality and B) its mechanism of action compared to 
that of other ncRNAs. 
 
 
 
Among drugs used for molecular targeting, monoclonal antibodies have led 
great benefits in a wide range of applications. However, there are several 
limitations related to antibodies; monoclonal antibodies normally are unable of 
membrane penetration due to larger size and thus, are not ideal as carriers for 
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targeted delivery of molecules within cells. They are also immunogenic, 
temperature sensitive, and their production is laborious, expensive, time 
consuming and undergoes batch-to-batch variations.  
Aptamers generally considered being oligonucleotides comparable to 
antibodies, rival antibodies in many ways. Aptamers fold to form unique 
tertiary structures, allowing them to bind to target proteins with high specificity 
and affinity, often leading to modulation of the target protein activity. In 
addition, aptamers small size enables them to access protein epitopes and be 
internalized better than antibodies. This feature allows aptamer to be used as 
bifunctional ligands that, along with recognition, can also be employed as 
delivery vehicles. These molecules are highly temperature-resistant and are 
stable over long-term storage. Their targeted binding properties can be 
controlled and modified as preferred, and molecules can be derivatized easily 
for downstream applications. Due to these advantages, aptamers gained 
immediate attention for clinical development, and shortly after the advent of 
the technology, a substantial number of aptamers entered clinical trials for a 
wide range of applications (Dua et al 2011). 
Over last years, the development of aptamers as therapeutics has mainly 
involved aptamers that bind and hamper the activity of their protein targets. To 
date, the most successful therapeutic application of an aptamer is represented 
by the RNA-aptamer commercially known as Macugen (or Pegaptanib, 
marketed by Eyetech Pharmaceuticals/Pfizer), that binds and blocks VEGF 
activity. The aptamer has been approved by the Food and Drug Administration 
for the treatment of age-related macular degeneration (AMD) (Katz and 
Goldbaum 2006). 
Recently, Camorani et al. (2014) have developed a new 33 mer nuclease-
stabilized RNA aptamer, named Gint4.T that specifically binds PDGFRβ by 
inhibiting the receptor activity and downstream signaling in glioblastoma 
multiforme (GBM) cells and in vivo (Figure 8). Gint4.T binds to PDGFRβ at 
high affinity and specificity and dramatically inhibits in vitro GBM cell 
migration and cell proliferation. Importantly, the potent inhibitory effect of 
Gint4.T has been extended to a xenograft model of GBM in which Gint4.T 
induces a remarkable tumor growth inhibition.  
Therefore, Gint4.T represents an innovative aptamer-based therapeutic tool that 
in combinations with conventional therapeutics may offer more effective 
alternative to treat cancer patients. 
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Figure 8. Gint4.T aptamer activity. Gint4.T specifically binds PDGFRβ by 
inhibiting the receptor activation and downstream signaling. 
 
 
 
1.5.2 Targeting Triple-Negative Breast Cancer microenvironment 
 
 
Breast cancer is one of the most commonly diagnosed tumor and the second 
leading cause of cancer-related death in women after lung carcinoma (Siegel et 
al. 2012). Around 15% of invasive breast carcinoma is identified as triple 
negative breast cancer (TNBC), characterized for the lack expression of 
estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. This renders it 
more difficult to treat since most chemotherapies target one of the three 
receptors, so triple-negative cancers often require combination therapies. 
TNBCs are generally of a higher grade, more prevalent in young and African-
American people and are commonly associated with a poor outcome. The 
metastatic potential in TNBC is similar to that of other breast cancer subtypes, 
but these tumors are associated with a shorter median time to relapse and death 
(Hudis and Gianni 2011). 
Over past years, a number of new strategies for TNBC were tested in clinical 
trials, including poly (ADP-ribose) polymerase (PARP), PI3K and MEK 
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inhibitors (Mayer et al. 2014). However, TNBC is clearly a complex disease 
and current treatments have shown unsatisfactory outcomes due to the 
dispersed nature of this tumor. Therefore, understanding new molecular 
mechanisms underlying breast cancer progression is required to provide new 
therapeutic targets. 
Recent evidence has suggested that critical components of tumor stroma, 
including CAFs and TAMs, play a crucial role to promote breast cancer 
initiation, growth, migration, metastasis and therapeutic resistances (Mao et al. 
2013). In addition, it has been widely shown that BM-MSCs can integrate into 
the tumor-associated stroma and promote the progression of TNBC through the 
activation of different mechanisms involving HIFs (Chaturvedi et al. 2013), 
TGF-β (McAndrews et al. 2015) and interleukin-1 beta (IL-1β) (Escobar et al. 
2015). Thus, exploring the interaction between cancer cells and stromal cells in 
the TNBC microenvironment may be useful to screen potential candidate 
markers and offer a great impact in TNBC therapy in the future. 
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2. AIM OF THE STUDY 
 
 
 
Tumor is a complex system in which cancer cells perform an intricate cross-
talk with microenvironment. A tumor can influence its microenvironment by     
releasing extracellular signals, promoting tumor angiogenesis and inducing the 
inflammatory response, whereas the stroma cells in the microenvironment can 
prompt tumor growth and promote metastatic phenotype. 
Thus, in this scenario, multi-targeted approaches, for both tumor cells and 
tumor microenvironment and/or the signaling pathways involved in their 
communication, may provide a more efficient anti-cancer therapy. 
Among several cell types that compose the tumor milieu, bone marrow-derived 
mesenchymal stem cells (BM-MSCs) selectively migrate toward tumor 
microenvironment and promote cancer progression and metastasis by 
supporting tumor stroma activity. 
The aim of this study is to investigate the role of BM-MSCs in tumor 
processes, deepening the involvement of specific signaling pathways 
underlying their recruitment and activity into tumor microenvironment.  
In particular, innovative therapeutic tools targeting specific receptor involved 
in the cross-talk between BM-MSCs and tumor cells have been developed and 
characterized to:  
- inhibit BM-MSC-mediated growth and aggressiveness of osteosarcoma 
(OS) and hepatocellular carcinoma (HCC) cell lines through 
modulation of CXCR4 signaling using a novel antagonist, named 
Peptide R. 
- interfere with BM-MSC recruitment by triple negative breast cancer 
(TNBC) cells through modulation of PDGFRβ signaling using Gint4.T 
aptamer. 
 
 
 
 
 
 
 
 
 
 
 
32 
 
3. MATERIALS AND METHODS 
 
 
 
3.1 Cell lines and culture conditions 
 
 
Human tumor cell lines were cultured in three different media: 
- osteosarcoma (OS) cells U2OS and Saos-2 were cultured in McCoy’s 
5A medium; 
- hepatocellular carcinoma (HCC) cells SNU-398 and Hep3B, U87MG 
glioblastoma and MCF7 breast cancer cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM);  
- triple-negative breast cancer cell lines (TNBC) MDA-MB-231 and BT-
549 were grown in RPMI 1640.  
All cell lines came from American Type Culture Collection, whereas OS cell 
lines were purchased from Sigma Aldrich. 
All types of media were supplemented with 10% fetal bovine serum (FBS), 
100 U/ ml penicillin and 100 μg/ml streptomycin. The cells were maintained in 
a humidified incubator in 5% CO2 at 37 °C. 
 
 
 
3.2 Isolation, culture and immunophenotypic characterization of human 
bone-marrow mesenchymal stem cells (BM-MSCs) 
 
 
Bone marrow (BM) samples were obtained from 3 male patients (29, 35 and 
49 years old) who underwent surgery at the Rizzoli Orthopaedic Institute after 
informed consent was obtained according to a protocol approved by the Ethics 
Committee. The isolation of cells and the expansion of cultures of human BM-
MSCs were performed, using gradient separation and plastic adherence 
methods (Pierini et al. 2012). BM-MSCs were recognized by their ability to 
proliferate in culture and their adherent, spindle-shape morphology. 
Furthermore, BM-MSCs were characterized using a FC500 flow cytometer 
(Beckman Coulter, Brea, CA, USA) with staminal markers; cells positive for 
CD44, CD73, CD90, CD105, and CD146 and negative for CD34 and CD45 
were isolated.  
BM-MSCs, after isolation and characterization, were grown in Alpha MEM 
medium supplemented with 20% FBS, 2mM GlutaMax (Gibco) and 100 U/ ml 
penicillin and 100 μg/ml streptomycin.   
To obtain conditioned medium (BM-MSC-CM), BM-MSCs were grown in 
medium with 1% FBS for 48 h. The medium was then collected, centrifuged at 
1000 × g for 10 min, and filtered through 0.22-μm filters (Millipore, Billerica, 
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MA), before being added to tumor cells. BM-MSCs were used at passage 2–3 
in this study.  
 
 
 
3.3 Aptamers and treatments 
 
 
2′F-Py RNA aptamers (Gint4.T and CL4Scrambled) were synthesized by 
TriLink Biotechnologies and purchased from Tebu-bio srl (Magenta, Milan, 
Italy).  
Before each treatment, aptamer proper folding was accomplished by a short 
denaturation/ renaturation step (85 °C for 5 minutes, snap-cooled on ice for 2 
minutes, and allowed to warm up to 37 °C). For cell incubation longer than 24 
hours, the aptamer treatment was renewed each day and the RNA concentration 
was determined to ensure the continuous presence of at least 400 nmol/l 
concentration, taking into account the 6 hours-half-life of the aptamer in 10% 
serum (Camorani et al. 2014). 
Gint4.T aptamer, PDGFRβ inhibitor: 
5’-UGUCGUGGGGCAUCGAGUAAAUGCAAUUCGACA-3’.  
The scrambled sequence of CL4 aptamer (Esposito et al. 2011) has been used 
as a negative control; herein indicated as unrelated: 
5’-UUCGUACCGGGUAGGUUGGCUUGCACAUAGAACGUGUCA-3’. 
 
 
 
3.4 Cell viability assay  
 
 
Cell viability was assessed with CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega, Madison, WI) according to the supplier’s 
instructions. The number of viable cells was detected by determining the 
bioreduction of 3-(4,5-dimethylthiazol- 2yl)-5-(3-carboxymethoxy-phenyl)-2-
(4-sulfophenyl)-2H tetrazolium (MTS)  to formazan salt crystals. 
U2OS and SNU-398 cells were seeded in their media at a density of 5000 cells 
per well in 96-well flat-bottomed plates and allowed to recover for 24 h. Then, 
tumor cells were grown in the presence of medium with 10% FBS or BM-
MSC-CM, or they were co-cultured with BM-MSCs (ratio 1:1) for 24 h and 48 
h in a humidified incubator with 5% CO2 at 37 °C. In co-cultures, BM-MSCs 
and tumor cells were grown in a Boyden chamber with a 0.4 μm membrane. 
The upper chambers were seeded with BM-MSCs, and the lower chambers 
were seeded with OS or HCC cells.  
BM-MSCs were seeded at a density of 4000 cells per well in 96-well flat-
bottomed plates and allowed to recover for 24 h. Then, BM-MSCs were treated 
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for 72 hours with 400nmol/l Gint4.T and the unrelated aptamer, or 1µmol/l 
Imatinib mesylate (Santa Cruz Biotechnology).  
After 1 h of incubation with MTS, the absorbance was read using a plate reader 
(Multiskan RC, Thermo Scientific) at a wavelength of 490 nm. Each sample 
was analyzed in triplicate. The data are expressed as the percentage of viable 
cells, considering 100% to represent the number of cells grown in the medium 
supplemented with 10% FBS, which was used as control.  
 
 
 
3.5 Cell lysate preparation and western blot analysis 
 
 
Cells were washed twice in ice-cold PBS and lysed in lysis buffer (40mM 
HEPES pH 7.5, 120mM NaCl, 5mM MgCl2, 1mM EGTA, 0.5 mM EDTA, 
and 1% Triton X-100) containing protease (Complete Tablets, EDTA-free, 
Roche) and phosphatase inhibitors (20mM α-glycerol-3-phosphate and 2.5 mM 
Na-pyrophosphate). The suspension was homogenized and centrifuged for 15 
min at 13,000 × g at 4 °C. Western blot analysis of proteins from whole cell 
lysates was performed using a standard protocol. Equal amounts of proteins 
from cells (50 μg) were separated using SDS-PAGE under reducing conditions 
and transferred to PVDF membranes. After blocking to prevent non-specific 
protein binding, the membranes were incubated with primary antibodies 
overnight at 4 °C. The following primary antibodies were used: rabbit 
polyclonal anti-CXCR4 (C8227, Sigma-Aldrich), rabbit polyclonal anti 
phospho-AKT (CST-9271, Cell Signaling, indicated as pAKT), rabbit 
polyclonal anti-AKT (CST-9272, Cell Signaling), rabbit polyclonal anti 
phospho-ERK (CST-9101, Cell Signaling, indicated as p-ERK), rabbit 
polyclonal anti-ERK (CST-9102, Cell Signaling), goat anti E-cadherin (sc-
1500, Santa Cruz Biotechnology), rabbit polyclonal anti-vimentin (CST-5741, 
Cell Signaling), anti phospho-PDGFRβ (CST-3173, Cell Signaling indicated as 
pPDGFRβ), anti-PDGFRβ (CST-3169, Cell Signaling) and mouse monoclonal 
anti-β-actin (A4700, Sigma-Aldrich). The filters were then incubated with 
1:2000 peroxidase-labeled anti-mouse, anti-rabbit or anti-goat Ig antibodies 
(Amersham Biosciences Europe, Freiburg, Germany) for 1 h at 22 °C. After 
extensive washing, the immunoreactions were revealed using an enhanced 
chemiluminescence detection system (ECL) according to the manufacturer’s 
recommendations. Densitometric analyses were performed on at least two 
different expositions to assure the linearity of each acquisition using ImageJ 
software (v1.46r).  
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3.6 RNA isolation and realtime-polymerase chain reaction (Real time-
PCR) 
 
 
Total RNA was extracted from tumor cells and BM-MSCs using TRIzol 
reagent (Invitrogen, Grand Island, NY). Total extracted RNA (200 ng) was 
reverse transcribed using Superscript II RNase H-reverse transcriptase 
according to the manufacturer’s instructions (Invitrogen/Life Technologies, 
Carlsbad, CA, USA). Real-time PCR was performed using approximately 10 
ng of cDNA in a 25-µl SYBR Green reaction mixture, and an ABI Prism 7000 
(Applied Biosystems, Carlsbad, CA, USA) robocycler was used for 
amplification. The cycling conditions for the PCRs were as follows: initial 
denaturation (one cycle of 10 min at 95 °C) followed by 40 cycles of 
denaturation (15 s at 95 °C) and annealing (1 min at 60 °C). Subsequently, 
CXCR4 mRNA levels in tumor cells were quantified, and these expression 
levels were compared to GUSB mRNA levels. Instead, for quantitative analysis   
of PDGFRβ mRNA levels in BM-MSCs, they were compared to β-actin 
mRNA levels.  
The gene-specific primers used for the amplifications were as follows: 
 
CXCR4: 5′-TGAGAAGCATGACGGACAAG-3′ (forward) 
5′-AGGGAAGCGTGATGACAAAG-3′ (reverse) 
 
GUSB: 5′-AGCCAGTTCCTCATCAATGG-3′ (forward) 
5′-GGTAGTGGCTGGTACGGAAA-3′ (reverse) 
 
PDGFRβ: 5’-AGGACACGCAGGAGGTCAT-3’ (forward) 
5’-TTCTGCCAAAGCATGATGAC-3’ (reverse) 
 
β-actin: 5’-CAAGAGATGGCCACGGCTGCT-3’ (forward) 
5’-TCCTTCTGCATCCTGTCGGCA-3’ (reverse) 
 
 
 
3.7 RNA interference 
 
 
CXCR4-targeting siRNA (L-005139-00-05) and a corresponding control 
non-targeting siRNA (D-001810-10-05) were purchased from Dharmacon. 
Saos-2 and Hep3B cells were transfected using DharmaFECT siRNA 
transfection reagent and 100 nmol/l siRNAs according to the manufacturer’s 
protocol. Saos-2 and Hep3B cells were grown in culture medium after 
transfection for 72 h, and the down-regulation of targeted protein expression 
was assessed using Western blot analysis. 
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3.8 Analysis of OS and HCC cell migration by wound healing assay  
 
 
OS and HCC cell lines were seeded in 6-well plates and grown to confluent 
cell monolayers. Cells were then scratched with pipette tips to make wounds. 
The cells were then rinsed with PBS to remove the loosened cell debris. 
Culture medium containing 1% FBS, 10% FBS, BM-MSC-CM, BM-MSC-CM 
with the CXCR4 antagonist AMD3100 (10 μM) (Sigma-Aldrich) or Peptide R 
(10 μM) were then added to the cells and the plates were incubated at 37 °C in 
5% CO2 for 24 h and 48 h. In addition, wound healing assays were performed 
using Saos-2 and Hep3B cells that were grown in the presence of CXCR4 
siRNA or Scr siRNA for 72 h. The wounds were observed using phase contrast 
microscopy. As the cells migrated to fill the scratched area, images were 
captured using a digital camera (Canon) that was attached to a microscope 
(Leica) at time 0 and after 24 and 48 hours. The distance between the edges of 
the scratch was measured using ImageJ, the average distance was quantified 
and the extent of wound closure was determined as follows: wound closure (%) 
= 1 − (wound width tx/wound width t0) × 100.  
 
 
 
3.9 Analysis of BM-MSC migration using Boyden chamber 
 
 
To test BM-MSC migration a 24-well Boyden chambers (Corning, NY) 
containing inserts of polycarbonate membranes with 8 μm pores were used. 
BM-MSCs were harvested, suspended in serum free medium, and counted. 
Cells (0.2 x 105  in 100 μl serum-free medium per well) were then plated into 
each top chamber in the presence of 400 nmol/l Gint4.T and the unrelated 
aptamer or  5µmol/l Imatinib mesylate, and exposed to PDGF-BB (100 ng/ml), 
MDA-MB-231, BT-549 cells, or 10% FBS as inducers of migration (0.6 ml, 
lower chamber). 
After incubation for 24 h at 37 °C in a humidified incubator in 5% CO2, the 
non-migrating cells were removed from the top chamber using a cotton swab, 
and the cells that had migrated to the lower surface of the membrane insert 
were visualized by staining with 0.1% crystal violet in 25% methanol. The 
percentage of migrated cells was evaluated by eluting the crystal violet with 
1% sodium dodecyl sulfate and reading the absorbance at a 570 nm 
wavelength. 
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3.10 Tumor cell invasion assay 
 
 
To perform invasion assays, the top compartment of Boyden chambers was 
coated with 50 μl of diluted (1:3 in PBS) Matrigel (BD Biosciences, San Jose, 
CA). After coating, chambers were incubated at 37°C for 1h to allow Matrigel 
to solidify. OS (U2OS and Saos-2) and HCC (SNU-398 and Hep3B) cells were 
harvested, suspended in serum free medium, and counted. Cells (2.5 × 105 in 
100 μl serum-free medium per well) were then added to each top chamber. 
Medium containing 1% FBS (negative control), 10% FBS (positive control), 
BM-MSC-CM or BM-MSCs was added to the lower chamber as a 
chemoattractant. After incubation for 48 h at 37 °C in a humidified incubator in 
5% CO2, migrated cells were visualized and analyzed as described above. To 
block CXCR4, the cells were incubated with the CXCR4 inhibitors AMD3100 
or Peptide R at a concentration of 10 μM during the invasion assays. 
 
 
 
3.11 NIR fluorescent BM-MSC-labeling 
 
 
VivoTrack 680 Fluorescent Cell Labeling Agent (MW: 1173 gmol-1; A: 676 
nm; Em: 696 nm) was commercially obtained from PerkinElmer (Waltham, 
MA), dissolved in 1.3 mL of warm sterile PBS (final volume of 2.0 mL). BM-
MSCs (3 x 106) were resuspendend in 200 µL of sterile PBS and incubated with 
VivoTrack 680 (ratio 1:1, v/v) for 30 min at 37°C under agitation in the dark. 
Afterwards, the suspension was washed three times with PBS containing 1% 
FBS to remove excess cell labeling agent. At that time, VivoTrack 680-labeled 
cell viability was assessed microscopically by Tripan-blue exclusion 
(GibcoTM). To verify that the labelling process had been successfully 
succeeded, labelled cells were examined by flow cytometry (BD Accuri™ C6), 
using appropriate lasers and filters for detection of 680 nm wavelength.  
 
 
 
3.12 In vivo BM-MSC tracking by Fluorescence Molecular Tomography  
 
 
Human breast cancer cell line MDA-MB-231 were used for development of 
animal tumor models using nude CD-1 (Crl:CD1-Foxn1nu) mice (Charles River 
Laboratories, Wilmington, MA). Briefly, MDA-MB-231 xenografts were 
established by subcutaneous inoculation of 10 × 106 cells into the right 
posterior flank of female nude CD-1 mice, 5 week old and weighing 15–20 g, 
and allowed to grow for 3 weeks.  
38 
 
To perform in vivo imaging studies, 1 × 106 VivoTrack 680-labeled BM-MSCs 
were administered by caudal vein injection in MDA-MB-231 xenografts. Mice 
under isoflurane anesthesia were analyzed at different time points by FMT 
4000 (Fluorescence Molecular Tomography) imaging system (PerkinElmer, 
Waltham, MA). 
Epifluorescence (2D) and tomography (3D) datasets were both acquired and 
analyzed by FMT system software (TrueQuantTM v4.0) from PerkinElmer 
(Waltham, MA). Volumes of interest (VOI’s) were drawn encompassing each 
tumor and quantitative measurement of fluorescence was performed and 
fluorochrome concentration to the pmol was obtained. 
All animal experimental procedures were conducted in accordance with Italian 
law for animal protection and were approved by the Italian Ministry of Health, 
Animal Welfare Direction. 
 
 
 
3.13 Statistical analysis 
 
 
Results were obtained from at least three independent experiments and are 
expressed as the mean ± standard deviation. The data were analyzed using 
GraphPad Prism statistical software 6.0 (GraphPad Software, La Jolla, CA, 
USA), and significance was determined using Student’s t-tests. A P-value 
<0.05 was considered statistically significant. 
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4. RESULTS 
 
 
 
4.1 BM-MSCs promote tumor cell growth and increase p-AKT and p-
ERK levels in human osteosarcoma (OS) and human hepatocellular 
carcinoma (HCC) cell lines 
 
 
To determine the effects of BM-MSCs on human osteosarcoma (U2OS) and 
human hepatocellular carcinoma cells (SNU-398) proliferation, cells were 
grown in medium supplemented with 10% FBS (control), in BM-MSC-
conditioned medium or co-cultured with BM-MSCs for 24 and 48 hours, and 
cell viability was then tested using an MTS assay. As shown in Figure 9A, 
when U2OS cells were grown in the presence of BM-MSC-CM for 24 and 48 
hours, a 2-fold significant increase in proliferation was observed compared to 
proliferation in the control cells (P < 0.01). Consistent with these results, I 
found that when U2OS cells were co-cultured with BM-MSCs (1:1 ratio), their 
growth was also significantly enhanced by 3- and 3.5-fold at 24 and 48 hours, 
respectively (P < 0.01) (Figure 9A). Similarly, I observed an increase in SNU-
398 cell proliferation when cells were grown in the presence of BM-MSC-CM 
(1.8-fold at 24h and 2.1-fold at 48h; P < 0.01) or co-cultured with BM-MSCs 
(1:1 ratio) (1.5-fold at 24h and 1.8- fold at 48h; P < 0.01) compared to 
proliferation in the control cells (Figure 9B). Thus, BM-MSCs and factors 
released by BM-MSCs promoted cell growth in U2OS and SNU-398 cells. 
To investigate the mechanisms underlying the promotion of tumor growth by 
BM-MSCs, I next analyzed the activation of cell survival-related intracellular 
signals in the PI3K/AKT and extracellular signal-regulated kinase 1/2 
(ERK1/2) pathways. As shown in Figure 9C, conditioned medium from BM-
MSCs increased p-AKT and p-ERK levels in both tumor cell lines compared to 
the levels observed in cells grown in medium supplemented with 10% FBS 
(control), whereas no increase was observed in AKT and ERK levels. I found 
that BM-MSC-CM caused a 2.54-fold and a 2.44-fold increase in p-AKT levels 
in U2OS and SNU-398 cells, respectively, whereas p-ERK was increased by 
1.3-fold in U2OS and 1.9-fold in SNU-398 cells compared to the levels 
observed in the controls (Figure 9C). 
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Figure 9. BM-MSCs enhance cell viability and activate AKT and ERK pathways 
in U2OS and SNU-398 tumor cell lines. (A, B) U2OS and SNU-398 cells were co-
cultured with BM-MSCs or grown in the presence of BM-MSC-CM for 24 and 48 
hours, and then their viability was tested using MTS assays. The data are expressed as 
the percentage of viable cells by considering 100% to represent the number of cells 
grown in medium supplemented with 10% FBS (controls). All experiments were 
performed at least three times independently (*P < 0.01). (C) Western blots show the 
effect of BM-MSC-CM after 24h on downstream signaling in tumor cells. Actin was 
used as an equal loading control. Representative data are shown from one of three 
experiments. The fold changes in p-AKT and p-ERK levels are shown in tumor cells 
grown in presence of BM-MSC-CM compared to their levels in control cells grown in 
medium containing 10% FBS, which were arbitrarily determined to be 1. 
 
 
 
4.2 BM-MSCs increase CXCR4 mRNA and protein expression in OS and 
HCC cell lines 
 
 
To test whether the expression of CXCR4 could be affected by treatment 
with BM-MSC-CM, OS (U2OS and Saos-2) and HCC cells (SNU-398 and 
Hep3B) were treated for 24h with BM-MSC-CM and a significant increase was 
observed in CXCR4 mRNA and protein levels (Figure 10). 
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Figure 10. BM-MSCs increase CXCR4 mRNA and protein levels in OS and HCC 
cell lines. (A) Western blot analysis of CXCR4 expression in tumor cell lines after 
treatment with BM-MSC-CM for 24h. Actin was used as an equal loading control. 
The values below the blot indicate signal levels relative to controls, which were 
arbitrarily set to 1 (labeled with asterisk). Representative data from one of three 
experiments are shown. (B) CXCR4 mRNA levels as detected using real-time PCR in 
OS and HCC cell lines grown for 24h in the presence of BM-MSC-CM, medium with 
1% FBS or medium with 10% FBS, as indicated. 
 
 
 
4.3 A novel CXCR4 antagonist, Peptide R, prevents BM-MSC-dependent 
wound healing in OS and HCC cells 
 
 
Because CXCR4 expression is correlated with tumor cell migration and 
metastatic potential (Thiery et al. 2009), I investigated whether BM-MSC-CM 
would be able to affect wound healing. Monolayers of U2OS and SNU-398 
cells were scratched, and images were taken at 0, 24 and 48 hours after 
wounding (Figure 11A and B). BM-MSC-CM caused a significant increase in 
wound closure in U2OS cells (64% and 82% at 24h and 48h, respectively) 
compared to closure in the control cells (1% FBS) (P < 0.01). When U2OS 
cells were grown in the presence of BM-MSC-CM and treated with 10 μM of 
CXCR4 antagonist Peptide R (indicated as PEP-R) or, alternatively, with 10 
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μM of AMD3100, wound healing was significantly delayed compared to cells 
treated with BM-MSC-CM alone (P < 0.001) (Figure 11A). In SNU-398 cells, 
BMMSC- CM caused a significant increase in wound closure (40% and 50% at 
24h and 48h, respectively) compared to closure in control cells, although this 
increase was lower than that observed for U2OS cells. These results suggest 
that Peptide R, as well as AMD3100, significantly reduced the wound closure 
induced by BM-MSC-CM (P < 0.001) (Figure 11B).  
To confirm that inhibition of CXCR4 expression reduced the BM-MSC-
induced wound closure, Saos-2 and Hep3B cells were transiently transfected 
with a pool of non-targeting Scr siRNAs or CXCR4-specific siRNAs. A 
significant reduction was observed in CXCR4 levels in both cell lines when 
they were transfected with CXCR4 siRNAs compared to cells transfected with 
Scr siRNAs for 72h (Figure 12A and B). Similar to what was observed in 
U2OS and SNU-398 cells, I observed that Saos-2 and Hep3B cells that were 
treated with BM-MSC-CM showed a significant increase in wound closure 
compared to closure in the control (1% FBS). Whereas when these cells were 
treated with BM-MSC-CM in presence of Peptide R (10 μM) or, alternatively, 
AMD3100 (10 μM), wound healing was significantly delayed (P < 0.001). 
Furthermore, when Saos-2 and Hep3B cells were transfected with CXCR4-
specific siRNAs, a significant reduction was observed in wound closure 
compared to closure in cells transfected with Scr siRNAs (P < 0.001) (Figure 
12A and B). 
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Figure 11. BM-MSCs induced an increase in wound healing in U2OS and SNU-
398 tumor cells that was inhibited by Peptide R. (A) U2OS cells, after wounds were 
made by scratching with pipette tips, were grown for 24 and 48 hours in medium 
containing 1% FBS or 10% FBS or with conditioned medium obtained from cultured 
BM-MSCs (BM-MSC-CM) in the presence of Peptide R (10 μM) or AMD3100 (10 
μM) used as positive control. (B) SNU-398 cells were tested in wound healing assays 
using the same experimental conditions described above for U2OS cells. The distance 
between edges of the scratch was measured using ImageJ, the average distance was 
quantified, and the extent of wound closure was determined as follows: wound closure 
(%) = 1 − (wound width tx/wound width t0) × 100. All experiments were performed at 
least three times. *P < 0.01 compared to the control (medium with 1% FBS); #P < 
0.001 compared to treatment with BM-MSC-CM. 
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Figure 12. The increase in wound healing in Saos-2 and Hep3B tumor cells 
induced by BM-MSCs was inhibited by Peptide R. (A) Saos-2 cells transfected for 
72 h with CXCR4-specific siRNAs or non-targeting siRNAs (used as the negative 
control) were analyzed to determine CXCR4 protein levels using western blot 
analysis. Saos-2 cells, after wounds were induced by scratching with pipette tips, were 
grown for 24 and 48 hours in medium containing 1% FBS or 10% FBS or with 
conditioned medium obtained from BM-MSCs (BM-MSC-CM) in the presence of 
CXCR4 inhibitor Peptide R (10 µM) or, alternatively, AMD3100 (10 µM), CXCR4 
siRNAs or Scr siRNAs, as indicated. (B) Hep3B cells were transfected and tested in 
wound healing assays using the same experimental conditions described above for 
Saos-2 cells. The distance between edges of the scratch was measured using ImageJ, 
the average distance was quantified, and the extent of wound closure was determined 
as follows: wound closure (%) = 1 − (wound width tx/wound width t0) × 100. All 
experiments were performed at least three times. *P < 0.01 compared to the control 
(medium containing 1% FBS); #P < 0.001 compared to BM-MSC-CM. 
 
 
 
4.4 A novel CXCR4 antagonist, Peptide R, prevents BM-MSC-dependent 
U2OS and SNU-398 cell invasion 
 
 
To test whether BM-MSCs could affect the invasiveness of U2OS and SNU-
398 cells, Boyden chambers coated with Matrigel were used. Figure 13A and B 
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demonstrate that a significant increase was observed in tumor cell invasiveness 
when the tumor cell line was exposed for 48 hours to BM-MSC-CM or BM-
MSCs (ratio 1:1), which was added to the lower chamber as chemoattractant, 
compared to the invasiveness observed in the control cells (1% FBS used as the 
medium) (P < 0.001). The inhibition of CXCR4 using Peptide R or AMD3100 
as positive control, dramatically suppressed the invasiveness of U2OS and 
SNU-398 cells that was promoted by BM-MSCs (P < 0.001). A similar 
inhibitory effect on BM-MSC-induced invasiveness was observed on Saos-2 
and Hep3B cells when they were also cultured in the presence of Peptide R, as 
well as AMD3100. (Figure 14A and B). 
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Figure 13. Peptide R prevents BM-MSC-mediated U2OS and SNU-398 tumor cell 
invasion. Tumor cells were seeded into upper chambers containing 8 μm pore-size 
filters that were coated with Matrigel basement membrane matrix in the presence or 
absence of Peptide R (10 μM) or, alternatively, AMD3100 (10 μM). Medium 
containing 1% FBS or 10% FBS, BM-MSCs or conditioned medium obtained from 
cultured BM-MSCs (BM-MSC-CM) were added to the lower chamber as a 
chemoattractant. The invasiveness of U2OS and SNU-398 cells is described in panels 
A and B, respectively. All experiments were performed at least three times. *P < 0.001 
compared to the control (medium with 1% FBS); #P < 0.001 compared to BM-MSCs. 
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Figure 14. Peptide R prevents BM-MSC-mediated Saos-2 and Hep3B tumor cells 
invasion. Tumor cells were seeded into upper chambers containing 8 µm pore-size 
filters that were coated with Matrigel basement membrane matrix in the presence or 
absence of Peptide R (10 μM) or, alternatively, AMD3100 (10 μM). Medium 
containing 1% FBS, medium containing 10% FBS, BM-MSCs or BM-MSC-CM were 
added to the lower chambers as chemoattractants. The invasion of Saos-2 cells and 
Hep3B cells is shown in panels A and B, respectively. All experiments were 
performed at least three times. *P < 0.001 compared to the control (medium containing 
1% FBS); #P < 0.001 compared to BM-MSCs. 
 
 
 
4.5 Peptide R prevents BM-MSC-dependent ERK and AKT activation and 
Epithelial-Mesenchymal Transition in OS and HCC cell lines 
 
 
To further characterize the involvement of ERK and AKT pathways in OS 
and HCC migration and invasion induced by BM-MSCs and triggered by 
CXCR4, I analyzed p-ERK and p-AKT expression after that cells were treated 
with the CXCR4-specific antagonist Peptide R and AMD3100 used as positive 
control. As shown in Figure 15, I observed a significant reduction in p-ERK 
and p-AKT levels when all cell lines, grown in presence of BM-MSC-CM, 
were treated with Peptide R, as well as, AMD3100. The epithelial–
mesenchymal transition (EMT) of tumor cells is widely accepted to be closely 
correlated with cancer metastasis (Yao et al. 2011). To explore whether 
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CXCR4 promotes EMT process in OS and HCC cell lines grown in the 
presence of BM-MSC-CM, I analyzed E-cadherin and vimentin levels after cell 
treatment with Peptide R and AMD3100. As shown in Figure 16, Peptide R as 
AMD3100 caused an increase in E-cadherin and a reduction in vimentin levels 
in cells that were grown in the presence of BM-MSC-CM. 
 
 
 
 
 
Figure 15. Peptide R prevents BM-MSC-dependent activation of ERK and AKT 
signaling pathways in OS and HCC cell lines. Tumor cell lines grown in the 
presence of BM-MSC-CM were treated with Peptide R, using AMD3100 as positive 
control, for 24h and then analyzed for p-ERK, ERK, p-AKT, and AKT levels. Actin 
was used as an equal loading control. Values below the blot indicate signal levels 
relative to controls (BM-MSC-CM), which were arbitrarily set to 1 (labeled with an 
asterisk). Representative data from one of three experiments are shown. 
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Figure 16. Peptide R prevents BM-MSC-dependent EMT in OS and HCC cell 
lines. Tumor cell lines grown in the presence BM-MSC-CM were treated with Peptide 
R, using AMD3100 as positive control, and analyzed for E-cadherin and Vimentin 
levels. Actin was used as an equal loading control. Values below the blot indicate 
signal levels relative to controls (BM-MSC-CM), which were arbitrarily set to 1 
(labeled with an asterisk). Representative data from one of three experiments are 
shown. 
 
 
 
4.6 BM-MSCs show high levels of PDGFRβ mRNA and protein 
 
 
Firstly, to determine BM-MSC expression of PDGFRβ, western blotting and 
Real Time-PCR analysis were performed using human glioblastoma cells 
U87MG and human breast cancer cells MCF7 as positive and negative control, 
respectively.  BM-MSCs showed higher levels of PDGFRβ protein (A) and 
mRNA (B) than U87MG cells used as positive control (Figure 17). 
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Figure 17. BM-MSCs present high PDGFRβ mRNA and protein levels. (A) 
Western blot analysis of PDGFRβ expression in BM-MSCs compared to U87MG and 
MCF7 cells as positive and negative control, respectively. Equal loading was 
confirmed by immunoblot with anti-actin antibody. Values below the blots indicate 
signal levels relative to U87MG cells arbitrarily set to 1 (labeled with asterisk). 
Representative data from one of three experiments are shown. (B) PDGFRβ mRNA 
levels as detected using Real Time-PCR in BM-MSCs compared to U87MG and 
MCF7 cells used as positive and negative control, respectively. 
 
 
 
4.7 Gint4.T aptamer inhibits PDGFRβ-mediated signaling pathway in 
BM-MSCs 
 
 
As a next step, I asked whether, because of its binding to PDGFRβ, Gint4.T 
aptamer could interfere with BM-MSC ligand-dependent activation of the 
receptor and downstream signaling. As shown in Figure 18A, Gint4.T (400 
nmol/l) treatment reduced the tyrosine-phosphorylation of PDGFRβ induced 
by PDGF-BB in BM-MSCs. No effect was observed when BM-MSCs were 
treated with the unrelated sequence used as a negative control. Furthermore, a 
substantial reduction of PDGF-BB-dependent phosphorylation of ERK1/2 and 
PKB/AKT kinase was observed in the presence of Gint4.T treatment (Figure 
18B). 
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Figure 18. Gint4.T aptamer inhibits PDGF-BB-dependent PDGFRβ activation in 
BM-MSCs.  Serum-starved BM-MSCs were stimulated with PDGF-BB in the 
presence of Gint4.T or the unrelated aptamer (used as a negative control), as indicated. 
Cell lysates were immunoblotted with (A) anti-p-PDGFRβ and anti-PDGFRβ, and 
with (B) anti-pERK and anti-pAKT. Values below the blots indicate signal levels 
relative to PDGF-BB stimulated cells in the presence of unrelated aptamer, arbitrarily 
set to 1 (labeled with asterisk). Equal loading was confirmed by immunoblot with anti-
actin antibody. Representative data are shown from one of three experiments. 
 
 
 
4.8 Gint4.T aptamer inhibits BM-MSC proliferation and migration 
 
 
Based on the Gint4.T inhibitory potential on the activation of ERK1/2 and 
the PKB/AKT pathways in BM-MSCs, I investigated whether PDGFRβ 
inhibition by Gint4.T aptamer could affect BM-MSC viability. Cells were 
treated with Gint4.T or an unrelated aptamer for 72 h and their growth was 
evaluated by MTS assay. As shown in Figure 19A, Gint4.T aptamer 
significantly inhibited cell viability of BM-MSCs and its effect was stronger 
than imatinib, a well known inhibitor of PDGFRβ activity (Maass et al. 2014). 
Remarkably, no cytotoxicity was observed when BM-MSCs were treated with 
the unrelated aptamer. 
Because PDGFRβ intracellular pathway has been reported to be involved in 
BM-MSC tropism for tumor sites (Hata et al. 2010), I determined whether 
Gint4.T aptamer could affect in vitro migration of BM-MSCs. BM-MSCs were 
seeded into the upper compartment of Boyden chamber, and grown in presence 
or not of Gint4.T aptamer for 24 h. Medium supplemented with 10% FBS was 
added into the lower compartment and used as chemoattractant. As shown in 
Figure 19B, the treatment with Gint4.T aptamer or imatinib strongly reduced 
BM-MSC migration whereas no effect was observed when cells were treated 
with an unrelated aptamer. 
54 
 
 
 
 
Figure 19. Gint4.T aptamer inhibits BM-MSC proliferation and migration. (A) 
BM-MSCs were treated for 72 hours with Gint4.T (400 nmol/l), the unrelated aptamer 
(400 nmol/l) used as a negative control or imatinib (1 µmol/l) used as positive control. 
Cell viability is expressed as percent of viable cells and untreated cells are reported as 
100%. All experiments were performed at least three times. *P < 0.01 imatinib vs 
untreated; **P < 0.001 Gint4.T vs untreated; #P < 0.01 Gint4.T compared vs unrelated 
aptamer. (B) Migration of BM-MSCs was analyzed by Boyden chamber in the 
presence of 400 nmol/l Gint4.T and the unrelated aptamer or 5 µmol/l imatinib for 24 
hours toward 10% FBS as chemoattractant. The migrated cells were stained with 
crystal violet. Representative photographs of at least three different experiments are 
shown. The results are expressed as percent of migrated cells respect untreated cells 
reported as 100%. All experiments were performed at least three times. **P < 0.001 
for imatinib and Gint4.T vs untreated; ##P < 0.001 for Gint4.T vs unrelated aptamer. 
 
 
 
4.9 Gint4.T aptamer prevents BM-MSC migration towards triple negative 
breast cancer (TNBC) cells  
 
 
To evaluate the role of PDGFRβ in BM-MSC migration towards TNBC cells, 
BM-MSCs were seeded in presence or not of Gint4.T aptamer into the upper 
compartment of Boyden chamber whereas two TNBC cell lines (MDA-MB-
231 or BT-549), and PDGF-BB were added into lower chamber as 
chemoattractants. As shown in Figure 20, the treatment of BM-MSCs with 
Gint4.T aptamer strongly reduced their migration towards MDA-MB-231 cells 
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(A), BT-549 cells (B)  and PDGF-BB (C), whereas no effect was observed 
after the unrelated aptamer treatment. 
 
 
 
 
 
Figure 20. Gint4.T aptamer inhibits BM-MSC migration towards TNBC cells. 
Migration of BM-MSCs was analyzed by Boyden chamber in the presence of Gint4.T 
or the unrelated aptamer, used as a negative control, for 24 hours. MDA-MB-231 cells 
(A), BT-549 cells (B) and PDGFBB (C) were added to the lower chambers. The 
migrated cells were stained with crystal violet. Representative photographs of at least 
three different experiments were shown. The results are expressed as percent of 
migrated cells and untreated cells are reported as 100%. All experiments were 
performed at least three times. *P < 0.01 compared to untreated cells; #P < 0.01 
compared to the unrelated aptamer; ##P < 0.001 compared to the unrelated aptamer. 
 
 
 
4.10 In vivo tracking of BM-MSC recruitment into TNBC xenograft by 
Fluorescence Molecular Tomography 
 
 
To test the ability of BM-MSCs to migrate towards tumors, cells were 
labeled with VivoTrack 680 Fluorescent Cell Labeling Agent and, then, 
examined for viability. There was essentially no significant loss of cell viability 
after incubation with VivoTrack 680. Therefore, these results demonstrated 
that an incubation time of 30 min with a dye concentration of 0.2 mg/ml was 
appropriate for stem cell labeling. The labeling efficiency of VivoTrack 680 
56 
 
was more than 99% at this labeling condition as established by flow cytometry 
(Figure 21).  
 
 
 
 
 
Figure 21. VivoTrack 680 efficiently labels BM-MSCs. BM-MSCs were incubated 
with VivoTrack 680 for 30 min and the dye uptake was analyzed by flow cytometry. 
Unlabeled and labeled BM-MSC mean fluorescence intensity is shown. 
 
 
 
Because VivoTrack 680 showed superior properties for stem cell labeling, the 
next aim was to investigate its feasibility for in vivo cell imaging and tracking. 
Nude mice bearing MDA-MB-231 xenografts, that received intravenous 
injections of 1 × 106 VivoTrack 680-labeled BM-MSCs, were analyzed with 
Fluorescence Molecular Tomography (FMT) at different time-points. Mice 
were analyzed in dorsal and lateral views and 3D images were reconstructed. 
Then, volumes of interest (VOIs) were generated around the tumor. The 
fluorescence signal of BM-MSCs was visualized in tumor at 3 h post-injection 
and remained visualized up to 24 and 48 h post-injection (Figure 22A and B). 
Because VivoTrack 680 emits at NIR wavelength where autofluorescence and 
tissue absorbance are minimal, a low fluorescence was observed in the tissues 
around the tumor. 
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Figure 22. In vivo imaging of VivoTrack 680-labeled BM-MSCs in Triple 
Negative breast cancer by Fluorescence Molecular Tomography. (A) Whole body 
lateral view of nude mouse bearing MDA-MB-231 xenograft (arrow) (B) 
Representative 3D image of tumor 3 h after intravenous injection of VivoTrack 680-
labeled BM-MSCs. The fluorescence signal was specifically detected in the tumor. 
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5. DISCUSSION 
 
 
Since the tumor microenvironment contributes to many aspects of 
carcinogenesis and cancer progression, the different stromal cell types which 
play key roles in determining or enhancing several hallmark capabilities in 
different TMEs, should be taken into account to stimulate future anticancer 
drug development. In particular, the recent discovery that mesenchymal stem 
cells (MSCs) can be recruited into tumor microenvironment and promote 
cancer progression has led to consider MSCs as a suitable target for an anti-
cancer therapy. In fact, great interest has been shown in developing therapeutic 
targeting strategies aimed to inhibit MCS support thus improving therapeutic 
efficacy in treating cancer (Shangguan et al. 2012, Shinagawa et al. 2013).  
In this study, I test two innovative therapeutic tools that, by targeting specific 
signaling pathways, prevent bone marrow-derived mesenchymal stem cells 
(BM-MSC) recruitment and activity into tumor microenvironment. 
Over last years, several studies have demonstrated that the effects of MSCs on 
tumor cells are numerous and controversial, which make the analysis of their 
role in cancer progression more complex. An increasing number of evidence 
has shown that MSCs can be recruited into primary tumors and become active 
components of the tumor microenvironment, including cancer-associated 
fibroblasts (CAFs) (Bergfeld and DeClerck 2010, Jung et al. 2013). 
Importantly, tumor associated-MSCs contribute to tumor cell growth and 
metastatic behavior in a variety of cancers, including breast (Chaturvedi et al. 
2013, Karnoub et al. 2007, Zhang et al. 2013), prostate (Jung et. al 2013, Luo 
et al. 2014, Zhang et al. 2013), osteosarcoma (Tu et al. 2012, Yu et al. 2015), 
and colon (Hogan et al. 2013, Liu et al. 2011, Shinagawa et al. 2013) cancers. 
In contrast, recent evidence showed that MSCs inhibit tumor progression. In 
glioblastoma multiforme (GBM), for example, MSCs seem to reduce tumor 
growth by inhibiting angiogenesis (Ho t al. 2013). Thus, in this scenario, the 
starting point for MSC targeted therapy is the identification of specific 
molecular pathways involved in pro-tumorigenic cross-talk between MSCs and 
cancer cells.  
In osteosarcoma (OS) several molecular pathways involved in MSC-mediated 
tumor progression were identified, including Interleukin-6/ Signal transducer 
and activator of transcription 3 (IL6/STAT3) (Tu et al. 2012), Chemokine (C-C 
motif) ligand 5 (CCL5) (Xu et al. 2009) and CXCR4/VEGF (Yu et al. 2015). 
For hepatocellular carcinoma (HCC), few studies have reported on the 
molecular mechanisms underlying the crosstalk between MSCs and HCC cells. 
Recently, Li et al. (2015) have showed that conditioned medium from rat BM-
MSCs enhance migration of a rat hepatoma cell line (CBRH-7919) by up-
regulating CXCR4. All these reports have demonstrated that in both, OS and 
HCC, the interaction between MSCs and cancer cells through specific signal 
pathways, promotes cell proliferation and migration/invasion in vitro, as well 
as tumor growth and metastasis development in vivo.  
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The delineation of key molecular pathways, that underlie the interactions 
between cancer and stroma cells, has improved the knowledge of the biology 
of tumor microenvironment, tumor spreading, and carcinogenesis. The 
complexities of cell-cell communication and the opportunities for modulation 
provide new possibility for cancer treatments. However, the understanding of 
the dynamic regulation of relationships between cells in the tumor 
microenvironment is still unclear. During tumor progression, cancer cells and 
the surrounding microenvironment constantly communicate each other through 
a biochemical and/or a biophysical signal. In this regard, paracrine molecules 
secreted by MSCs can act as ligands for receptors that are expressed on tumor 
cells, thereby inducing the activation of the PI3K/AKT and Ras/ERK 
pathways, which are involved in tumor cell progression (Huang et al. 2013). 
Consistent with these studies, I found that conditioned medium obtained from 
BM-MSCs causes parallel increases in OS and HCC cell growth and p-AKT/p-
ERK levels, suggesting the activation of the PI3K/AKT as well as the 
Ras/ERK intracellular cascades. 
Emerging evidence has shown that BM-MSCs may accelerate human breast 
tumor growth and metastasis by regulating the cancer stem cell population 
through a microenvironmental network of cytokines and growth factors (Liu et 
al. 2011). In addition, it was reported that MSCs are recruited into prostate 
tumors through CXCL16 and that they are then converted in to CAFs. In turn, 
CAFs secrete CXCL12, which binds to CXCR4 on tumor cells to induce EMT, 
which ultimately promotes metastasis to secondary tumor sites (Jung et. al 
2013). Thus, the CXCR4/CXCL12 axis results important for MSCs to promote 
cancer cells capacity to migration and invasion, making this pathway an 
important potential target for cancer therapeutics. In this study, when OS and 
HCC cells were treated with conditioned medium obtained from BM-MSCs an 
increase of mRNA and protein levels of CXCR4 was observed, suggesting that 
the cross-talk between BM-MSCs and tumor cells involved the 
CXCR4/CXCL12 axis. 
Recently, in order to overcome the toxicity of the well-known CXCR4 
antagonist AMD3100, Portella et al. (2013) developed a novel CXCR4 
antagonist suitable for anticancer therapy, Peptide R. In fact, although 
AMD3100 (known as Plerixafor) represents the most effective CXCR4 
therapeutic targeting, it has evoked some concerns regarding its cardiotoxicity 
and it is, therefore, not an ideal anticancer agent (Hendrix et al. 2004). Thus, in 
order to develop new CXCR4 antagonists suitable for anticancer therapy, the 
short structural motifs in the ligand receptor-binding region of CXCL12 was 
analyzed and, based on this scaffold, were designed short CXCR4-ligand 
peptides. Importantly, the entire peptide library was first evaluated for 
cytotoxicity on several human cancer cell lines and showed no toxicity. 
Subsequently, CXCR4 developed peptides were tested for their capability to 
bind CXCR4 and antagonize its activity, and Peptide R especially revealed the 
best efficacy both in in vitro and in vivo analysis on animal tumor models. 
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Here, for the first time it has been shown that Peptide R inhibits OS and HCC 
cells migration and invasion in response to BM-MSCs. In addition, to elucidate 
the mechanism underlying Peptide R activity, I have analyzed the role of 
PI3K/AKT and Ras/ERK pathways.  I have demonstrated that Peptide R 
prevents BM-MSC-dependent phosphorylation of ERK and AKT, thus 
inhibiting these signaling pathways in OS and HCC cell lines.  
Furthermore, I have investigated the role of BM-MSCs in another important 
mechanism involved in tumor progression, Epithelial-Mesenchymal Transition 
(EMT) process. EMT consists in the transition of tumor cells from epithelial to 
mesenchymal phenotype due to paracrine molecules produced by stromal cells 
of tumor microenvironment (Giannoni et al. 2012). This mesenchymal 
phenotype is associated with an increase of cellular motility and invasion that 
in turn enhances tumor malignancy. Here, I have demonstrated that Peptide R, 
targeting and inhibiting CXCR4, prevents EMT of OS and HCC cells promoted 
by BM-MSCs. Indeed, I have observed an increase of E-cadherin, epithelial 
marker, and a decrease of vimentin (mesenchymal marker) levels in tumor cells 
exposed to conditioned medium from BM-MSCs and treated with Peptide R.  
Thus, in this study for the first time, it has been assessed the possibility to use a 
novel CXCR4 inhibitor, Peptide R, as therapeutic agent to prevent the cancer 
progression and spreading that is regulated by cross-talk between BM-MSCs 
and tumor cells. 
Given the importance to identify mechanisms that underlie the recruitment of 
MSCs into tumor microenvironment, in this study, I have also analyzed one of 
the most important signaling pathway involved in the bidirectional 
communication between cancer cells and MSCs, the PDGFRβ pathway. 
Over past years, several studies have shown that MSCs express high levels of 
PDGFRβ (Ng et al. 2008, Spitzer et al. 2012), suggesting that it could play a 
crucial role in processes in which MSCs are involved. In fact, it is widely 
reported that PDGFRβ is implicated in specifying MSC commitment to 
mesenchymal lineages (Ng et al. 2008) as well as in MSC proliferation and 
self-renewal (Gharibi et al. 2012).  
Furthermore, PDGFRβ signaling has emerged as a predominant pathway in 
recruitment of MSCs towards tumor sites (Veevers-Lowe et al. 2011). Hata et 
al. (2010), for example, have demonstrated that PDGFRβ was involved in 
MSC tropism for malignant gliomas, providing direct evidence that tumor was 
capable of attracting MSCs in an in vivo intracranial glioma model through 
PDGFRβ pathway. In addition, due to MSC capability to suppress tumor 
growth in glioma (Ho et al. 2013, Nakamizo et al. 2005), Hata et al. suggested 
the possibility to exploit their findings for advancing MSC glioma treatment. In 
contrast with positive effects provided by MSCs in glioma, several studies have 
reported that PDGFRβ-mediated MSC recruitment into tumor 
microenvironment, contributed to enhance the aggressive and invasive 
properties of many types of tumor, including chronic lymphocytic leukemia 
(CLL) (Ding et al. 2010), pancreatic (Beckermann et al. 2008) and colon 
(Shinagawa et al. 2013) carcinomas.  
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However, although PDGFRβ inhibitors have already been tested for their 
capability to target and interfere with receptor activity in MSCs (Ball et al. 
2012, Gharibi et al. 2012, Hata et al. 2010), no studies have still demonstrated 
the possibility to target PDGFRβ to prevent pro-tumorigenic effect of MSCs 
into tumor microenvironment. Moreover, the current class of PDGFRβ drugs 
consist of small molecule TKIs that show limited specificity and modest 
efficacy whereas no antibodies have entered the clinic. To give more effective 
alternative to currently used PDGFRβ inhibitors, recently, Camorani et al. 
(2014) have developed a new 33 mer nuclease-stabilized RNA aptamer suitable 
for anticancer therapy, named Gint4.T. Aptamers respond to many 
requirements because they can discriminate among thousand proteins and do so 
in a short time. They can distinguish between small proteins that are otherwise 
relatively similar in structure, a necessary property if proteins are differentiated 
on the cell surface. 
Here, for the first time, I have tested an innovative aptamer-based therapeutic 
tool to interfere with PDGFRβ-dependent BM-MSC recruitment into breast 
cancer microenvironment. 
Accordingly with the involvement of PDGFRβ in MSC proliferation and 
migration (Gharibi et al. 2012, Veevers-Lowe et al. 2011), I have showed that 
Gint4.T significantly inhibits in vitro BM-MSC cell migration and blocks cell 
proliferation. To elucidate the mechanism underlying Gint4.T aptamer activity, 
I have investigated the role of PDGFRβ downstream pathways. I have found 
that the binding of the Gint4.T to PDGFRβ prevents ligand-dependent 
phosphorylation of the receptor and the consequent activation of ERK1/2 and 
AKT signaling.  
Recent evidence has widely shown that BM-MSCs can integrate into the 
tumor-associated stroma and promote the progression of triple negative breast 
cancer (TNBC) through the activation of different mechanisms involving HIFs 
(Chaturvedi et al. 2013), TGF-β (McAndrews et al. 2015) and interleukin-1 
beta (IL-1β) (Escobar et al. 2015).  
Up to now, no work has demonstrated the involvement of PDGFRβ pathway in 
MSC recruitment toward TNBC microenvironment, as well as MSC-mediated 
TNBC progression. In this study I have showed that Gint4.T aptamer, 
inhibiting PDGFRβ, strongly reduces BM-MSC migration stimulated by two 
different TNBC cell lines, MDA-MB-231 and BT-549, as well as by PDGFBB 
ligand. This result underlines the importance of PDGFRβ in mediating MSC 
migration towards TNBC cells and highlights Gint4.T aptamer to specifically 
prevent PDGFRβ-mediated MSC tropism for tumor microenvironment. 
These data demonstrated that Gint4.T aptamer not only hampers PDGFRβ 
phosphorylation and downstream signaling in BM-MSCs, but it also interferes 
with recruitment of BM-MSCs in breast cancer microenvironment. 
Thus, for the first time, it has been assessed the possibility to use a novel 
aptamer-based PDGFRβ inhibitor as therapeutic agent to prevent BM-MSC 
recruitment and eventually interfere with their pro-tumorigenic activity within 
tumor microenvironment. 
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6. CONCLUSIONS 
 
 
Knowing that BM-MSCs have a key role in promoting cancer progression, in 
my thesis I have investigated the possible pathways underling their recruitment 
and their pro-tumorigenic activity within tumor microenvironment. I 
demonstrated that CXCR4 is involved in tumor BM-MSC-mediated 
osteosarcoma and hepatocellular carcinoma invasion, whereas PDGFRβ plays 
a key role in BM-MSC migration towards triple negative breast cancer  cells, a 
well-known aggressive phenotype of breast cancer.  
After establishing the involvement of CXCR4 and PDGFRβ signaling 
pathways in the cross-talk between BM-MSCs and tumor cells, I validated the 
possibility to interfere with them by using two novel therapeutic tools, Peptide 
R and Gint4.T aptamer, respectively. 
In conclusion, this study provides insight into BM-MSC interactions with 
aggressive cancer cells and identifies potential therapeutic targets. 
Furthermore, for the first time innovative therapeutic tools targeting BM-MSCs 
and preventing their recruitment and activity are developed and validated. 
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Recent ﬁndings suggest that bone marrow-derived mesenchymal stem cells (BM-MSCs) are recruited into
the microenvironment of developing tumors, where they contribute to metastatic processes. The aim of
this study was to investigate the role of BM-MSCs in promoting osteosarcoma and hepatocellular car-
cinoma cell progression in vitro and the possible mechanisms involved in these processes.
U2OS and SNU-398 are osteosarcoma and hepatocellular carcinoma cell lines, respectively, that can
be induced to proliferate when cultured in the presence of BM-MSCs. To determine the effect of BM-
MSCs on U2OS and SNU-398 cells, the AKT and ERK signaling pathways were investigated, and increases
were observed in active P-Akt and P-Erk forms. Moreover, BM-MSCs caused an increase in tumor cell
migration and invasion that was derived from the enhancement of CXCR4 levels.
Thus, when tumor cells were treated with the CXCR4 antagonist AMD3100, a reduction in their mi-
gration and invasion was observed. Furthermore, a new CXCR4 inhibitor, Peptide R, which was recently
developed as an anticancer agent, was used to inhibit BM-MSC-mediated tumor invasion and to over-
come AMD3100 toxicity. Taken together, these results suggest that inhibiting CXCR4 impairs the cross-
talk between tumor cells and BM-MSCs, resulting in reduced metastatic potential in osteosarcoma and
hepatocellular carcinoma cells.
© 2015 Elsevier Ireland Ltd. All rights reserved.
Introduction
Tumor progression is a multistep process during which tumor-
associated stromal cells perform an intricate cross-talk with tumor
cells to supply appropriate signals that may promote tumor sur-
vival, proliferation and aggressiveness. A tumor can inﬂuence its
microenvironment by releasing extracellular signals, promoting
tumor angiogenesis and inducing the inﬂammatory response, while
the immune cells in the microenvironment can affect the growth
and evolution of cancer cells. The relationship between cancer cells
and their microenvironment contributes to tumor heterogeneity [1].
Mesenchymal stem cells (MSCs) are non-hematopoietic
multipotent stromal cells that are involved in tissue homeostasis
and regeneration. Normally, MSCs are rapidly recruited into sites
of injury and inﬂammation, where they differentiate into a variety
of connective tissue cell types [2]. Early studies demonstrated that
bone marrow-derived mesenchymal stem cells (BM-MSCs) possess
a remarkable ability to home in to tumor sites and putative immune-
privileged status that renders them suitable carriers for delivering
anti-tumor agents to the tumor microenvironment [3]. However,
BM-MSCs have also been identiﬁed as pro-active tumor stroma-
associated cells that are implicated in promoting cell survival,
angiogenesis, invasion, and metastasis in addition to the evasion of
the immune system [4]. Recently, tumor-associated BM-MSCs have
been reported to differentiate within the tumor microenviron-
ment and to act as local sources for other tumor stromal cells, such
as cancer-associated ﬁbroblasts (CAF) [5]. Furthermore, BM-MSCs
increased the population of cancer stem cells (CSCs) in breast [6]
and prostate carcinomas [7]. The cross-talk between tumor cells and
stromal cells induced the production of growth factors, cytokines
and chemokines that can speciﬁcally attract BM-MSCs to invade the
tumor microenvironment, as has been shown in breast [8], lung [9],
prostate [10] and colon [11] carcinomas. Even though BM-MSCs have
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been shown to integrate into the tumor stroma and promote tumor
progression, the molecular mechanisms underlying these pro-
cesses have remained elusive.
BM-MSC-derived chemokines, such as CXCL1, CXCL2 or CXCL12,
have been shown to promote cancer cell proliferation through the
related receptors CXCR2 and CXCR4 in a number of cancer models
[12,13].
The chemokine CXCL12, by binding to the CXCR4 and CXCR7 re-
ceptors, activates signaling pathways that result in cell proliferation,
cell migration and the transcriptional regulation of genes that are
critical for cell inﬂammation and cancer metastases [13,14]. CXCR4
expression was ﬁrst correlated with breast and melanoma cancer
cell metastatic progression [14,15]. As a result of its pleiotropic role
in tumor development, the CXCL12/CXCR4 axis is considered an im-
portant potential target for cancer therapeutics. A CXCR4 inhibitor,
the bicyclam plerixafor (formerly known as AMD3100), is ap-
proved by the FDA as a hematopoietic stem cell mobilizer in patients
with non-Hodgkin lymphoma and multiple myeloma refractory to
conventional protocols for mobilization [16]. Nevertheless, Plerixafor
has evoked some concerns regarding its toxicity and is therefore not
an ideal anticancer agent [17,18].
It has been shown that the CXCL12/CXCR4 pathway regulatesmo-
bilization, traﬃcking and homing in normal stem cells andmetastasis
in cancer stem cells [19]. Portella et al. [20] described a new family
of peptides that were rationally designed and that were not derived
from the naturally occurring CXCR4 inhibitor polyphemusin-II, which
has been used as a template to design several classes of CXCR4 in-
hibitors. These CXCR4 antagonists reduced lung metastasis in mice
injected with B16-CXCR4 mouse melanoma cells and K7M2 mouse
osteosarcoma cells [20].
Several studies have reported that BM-MSCs promoted the pro-
gression of osteosarcoma through different mechanisms involving
IL-6/STAT3 [21], the chemokine CCL5 [22], VEGF [23] and CXCR4 [24].
In hepatocellular carcinoma, rat BM-MSCs enhanced migration in
a rat hepatoma cell line (CBRH-7919) by up-regulating CXCR4 [25].
Conversely, Li T. et al. showed that BM-MSCs promoted prolifera-
tion in human hepatocellular carcinoma cells but inhibited their
migration [26].
In our study, we focused on two of the most common cancers
with a poor prognosis and metastatic recurrence in children and
adults: osteosarcoma (OS) and hepatocellular carcinoma (HCC)
[27,28]. Thus, we investigated the role of BM-MSCs in controlling
growth and aggressiveness in OS and HCC cell lines, and we ana-
lyzed the involvement of CXCR4 in these processes. Furthermore,
to interfere with cross-talk between BM-MSCs and tumor cells, we
tested a new CXCR4 inhibitor, Peptide R, which was developed to
overcome the toxicity of the well-known CXCR4 inhibitor AMD3100.
Materials and methods
Cell lines and culture conditions
The human osteosarcoma cell lines (OS) U2OS and Saos-2 were cultured in
McCoy’s 5A medium according to the instructions provided by Sigma-Aldrich. The
hepatocellular carcinoma (HCC) cell lines SNU-398 and Hep3B were purchased from
the American Type Culture Collection and grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM). Both types of media were supplemented with 10% FBS, 100 U/
ml penicillin and 100 μg/ml streptomycin. The cells were maintained in a humidiﬁed
incubator in 5% CO2 at 37 °C.
Isolation, culture and immunophenotypic characterization of human bone-marrow
mesenchymal stem cells (BM-MSC)
Bone marrow (BM) samples were obtained from 3 male patients (29, 35 and 49
years old) who underwent surgery at the Rizzoli Orthopaedic Institute after in-
formed consent was obtained according to a protocol approved by the Ethics
Committee. The isolation of cells and the expansion of cultures of human BM-
MSCs were performed as previously described [29], using gradient separation and
plastic adherence methods. BM-MSCs were recognized by their ability to prolifer-
ate in culture and their adherent, spindle-shape morphology. Furthermore, BM-
MSCs were characterized using a FC500 ﬂow cytometer (Beckman Coulter, Brea, CA,
USA) with staminal markers, and cells that were positive for CD44, CD73, CD90, CD105,
and CD146 and negative for CD34 and CD45 were isolated. BM-MSCs, after isola-
tion and characterization, were grown in medium with 1% fetal bovine serum for
48 h to obtain conditioned medium (BM-MSC-CM). The medium was then collect-
ed, centrifuged at 1000 × g for 10min, and ﬁltered through 0.22-μm ﬁlters (Millipore,
Billerica, MA) before being added to tumor cells. The BM-MSCs were used at passage
2–3 in this study.
Cell viability assay
To investigate the effects of BM-MSCs on cell viability, a 3-(4,5-dimethylthiazol-
2yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) assay
was performed according to the manufacturer’s instructions (Promega). As previ-
ously described [30], this colorimetricmethod allows the determination of the number
of viable cells based on the bioreduction of MTS to formazan salt crystals. In co-
cultures, BM-MSCs and tumor cells were grown in a Boyden chamber with a 0.4 μm
membrane. The upper chambers were seeded with BM-MSCs, and the lower cham-
bers were seeded with tumor cells. Brieﬂy, tumor cells were seeded at a density of
5000 cells per well in 96-well ﬂat-bottomed plates and allowed to recover for 24 h.
Then, tumor cells were grown in the presence of medium with 10% FBS or BM-
MSC-derived conditioned medium, or they were co-cultured with BM-MSCs (ratio
1:1) for 24 h and 48 h in a humidiﬁed incubator with 5% CO2 at 37 °C. After 1 h of
incubation with MTS, the absorbance was read using a plate reader (Multiskan RC,
Thermo Scientiﬁc) at a wavelength of 490 nm. Each sample was analyzed in tripli-
cate. The data are expressed as the percentage of viable cells, considering 100% to
represent the number of cells grown in the medium supplemented with 10% FBS,
which was used as the control. All experiments were independently performed at
least three times.
Cell lysate preparation and western blot analysis
Whole-cell lysates were prepared as previously described [31]. Brieﬂy, cells were
homogenized in lysis buffer (40mMHEPES pH 7.5, 120mMNaCl, 5mMMgCl2, 1mM
EGTA, 0.5 mM EDTA, and 1% Triton X-100) containing protease (Complete Tablets,
EDTA-free, Roche) and phosphatase inhibitors (20 mM α-glycerol-3-phosphate and
2.5 mM Na-pyrophosphate). The suspension was homogenized and centrifuged for
15min at 13,000 × g at 4 °C. Western blot analysis of proteins fromwhole cell lysates
was performed using a standard protocol. Equal amounts of proteins from cells (50 μg)
were separated using SDS-PAGE under reducing conditions and transferred to PVDF
membranes. After blocking to prevent non-speciﬁc protein binding, the mem-
branes were incubated with primary antibodies overnight at 4 °C. The following
primary antibodies were used: rabbit polyclonal anti-CXCR4 (C8227, Sigma-
Aldrich), rabbit polyclonal anti-AKT (CST-9272, Cell Signaling), rabbit polyclonal anti
P-AKT (CST-9271, Cell Signaling), rabbit polyclonal anti-ERK (CST-9102, Cell Signal-
ing), rabbit polyclonal anti P-ERK (CST-9101, Cell Signaling), goat anti E-cadherin (sc-
1500, Santa Cruz Biotechnology), rabbit polyclonal anti-vimentin (CST-5741, Cell
Signaling) and mouse monoclonal anti-β-actin (A4700, Sigma-Aldrich). The ﬁlters
were then incubated with 1:2000 peroxidase-labeled anti-mouse, anti-rabbit or anti-
goat Ig antibodies (Amersham Biosciences Europe, Freiburg, Germany) for 1 h at 22 °C.
After extensive washing, the immunoreactions were revealed using an enhanced che-
miluminescence detection system (ECL) according to the manufacturer’s
recommendations. Densitometric analyses were performed on at least two differ-
ent expositions to assure the linearity of each acquisition using ImageJ software
(v1.46r). The blots shown representative of at least three independent experiments.
RNA isolation and real-time reverse transcription polymerase chain reaction (PCR)
Total RNAwas extracted from tumor cells using TRIzol reagent (Invitrogen, Grand
Island, NY). Total extracted RNA (200 ng) was reverse transcribed using Super-
script II RNase H-reverse transcriptase according to the manufacturer’s instructions
(Invitrogen/Life Technologies, Carlsbad, CA, USA). Real-time PCRwas performed using
approximately 10 ng of cDNA in a 25-ml SYBR Green reaction mixture, and an ABI
Prism 7000 (Applied Biosystems, Carlsbad, CA, USA) robocycler was used for am-
pliﬁcation. The cycling conditions for the PCRs were as follows: initial denaturation
(one cycle of 10 min at 95 °C) followed by 40 cycles of denaturation (15 s at 95 °C)
and annealing (1 min at 60 °C). Subsequently, CXCR4 mRNA levels were quantiﬁed,
and these expression levels were compared to GUSB mRNA levels. All of the samples
were analyzed in triplicate using real-time PCR.
The gene-speciﬁc primers used for the ampliﬁcations were as follows:
CXCR4: 5′-TGAGAAGCATGACGGACAAG-3′ (forward)
5′-AGGGAAGCGTGATGACAAAG-3′ (reverse)
GUSB: 5′-AGCCAGTTCCTCATCAATGG-3′ (forward)
5′-GGTAGTGGCTGGTACGGAAA-3′ (reverse)
RNA interference
CXCR4-targeting siRNA (L-005139-00-05) and a corresponding control non-
targeting siRNA (D-001810-10-05) were purchased from Dharmacon. Saos-2 and
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Hep3B cells were transfected using DharmaFECT siRNA transfection reagent and
100 nmol/l siRNAs according to the manufacturer’s protocol. Saos-2 and Hep3B cells
were grown in culture medium after transfection for 72 h, and the down-regulation
of targeted protein expression was assessed using Western blot analysis.
Wound healing assays
OS and HCC cell lines were seeded in 6-well plates and grown to conﬂuent cell
monolayers. Cells were then scratched with pipette tips to make wounds. The cells
were then rinsed with PBS to remove the loosened cell debris. Culture medium con-
taining 1% FBS, 10% FBS, BM-MSC-CM, BM-MSC-CM with the CXCR4 antagonist
AMD3100 (10 μM) (Sigma-Aldrich) or Peptide R (10 μM) were then added to the cells
and the plates were incubated at 37 °C in 5% CO2 for 24 h and 48 h. In addition, wound
healing assays were performed using Saos-2 and Hep3B cells that were grown in
the presence of CXCR4 siRNA or Scr siRNA for 72 h. The wounds were observed using
phase contrast microscopy. As the cells migrated to ﬁll the scratched area, images
were captured using a digital camera (Canon) that was attached to a microscope
(Leica) at time 0 and after 24 and 48 hours. The distance between the edges of the
scratch was measured using ImageJ, the average distance was quantiﬁed and the
extent of wound closure was determined as follows: wound closure (%) = 1 − (wound
width tx/wound width t0) × 100. All experiments were performed at least three times.
Cell invasion assays
To perform invasion assays, 24-well trans-well chambers (Corning, NY) con-
taining inserts with polycarbonate membranes with 8 μm pores were used. The top
chamber, which contained the ﬁlter, was coated with 50 μl of diluted (1:3 in PBS)
Matrigel (BD Biosciences, San Jose, CA) following standard protocols. OS (U2OS and
Saos-2) and HCC (SNU-398 and Hep3B) cells were harvested, suspended in serum-
free medium, and counted. Cells (2.5 × 105 in 100 μl serum-free medium per well)
were then added to each top chamber. Medium containing 1% FBS (negative control),
10% FBS (positive control), BM-MSC-CM or BM-MSCs was added to the lower chamber
as a chemoattractant. After incubation for 48 h at 37 °C in a humidiﬁed incubator
in 5% CO2, the non-invading cells were removed from the top chamber using a cotton
swab, and the cells that had migrated to the lower surface of the membrane insert
were visualized by staining with 0.1% crystal violet in 25% methanol. The percent-
age of migrated cells was evaluated by eluting the crystal violet with 1% sodium
dodecyl sulfate and reading the absorbance at a 570 nm wavelength. The data were
obtained from three independent experiments. To block CXCR4, the cells were in-
cubated with the CXCR4 inhibitors AMD3100 or Peptide R at a concentration of 10 μM
during the invasion assays.
Statistical analysis
Results were obtained from at least three independent experiments and are ex-
pressed as the mean ± standard deviation. The data were analyzed using GraphPad
Prism statistical software 6.0 (GraphPad Software, La Jolla, CA, USA), and signiﬁ-
cance was determined using Student’s t-tests. A P-value <0.05 was considered
statistically signiﬁcant.
Results
BM-MSCs promote tumor cell growth and increase P-Akt and P-Erk
levels
To determine the effects of BM-MSCs on human osteosarcoma
cell (U2OS) and human hepatocellular carcinoma cell (SNU-398)
growth, cells were grown in medium supplemented with 10% FBS
(control), in conditioned medium obtained from BM-MSC cul-
tures or co-cultured with BM-MSCs for 24 and 48 hours, and cell
viability was then tested using an MTS assay. As shown in Fig. 1A,
when U2OS cells were grown in the presence of BM-MSC-CM for
24 and 48 hours, a 2-fold signiﬁcant increase in proliferation was
observed compared to proliferation in the control cells (P < 0.01).
Consistent with these results, we found that when U2OS cells were
co-cultured with BM-MSCs (1:1 ratio), their growth was also sig-
niﬁcantly enhanced by 3- and 3.5-fold at 24 and 48 hours,
respectively (P < 0.01) (Fig. 1A). Similarly, we observed an increase
in SNU-398 cell proliferation when cells were grown in the pres-
ence of BM-MSC-CM (1.8-fold at 24 h and 2.1-fold at 48 h; P < 0.01)
or co-cultured with BM-MSCs (1:1 ratio) (1.5-fold at 24 h and 1.8-
fold at 48 h; P < 0.01) compared to proliferation in the control cells
Fig. 1. BM-MSCs enhance cell viability and activate the P-AKT/AKT and P-ERK/ERK pathways in U2OS and SNU-398 tumor cell lines. (A) U2OS and SNU-398 cells were co-
cultured with BM-MSCs or grown in the presence of BM-MSC-CM for 24 and 48 hours, and then their viability was tested using MTS assays. The data are expressed as the
percentage of viable cells by considering 100% to represent the number of cells grown in medium supplemented with 10% FBS (controls). All experiments were performed
at least three times independently (*P < 0.01). (B) Western blots show the effect of BM-MSC-CM after 24 h on downstream signaling in tumor cells. Actin was used as an
equal loading control. Representative data are shown from one of three experiments. The fold changes in P-AKT and P-ERK levels are shown in tumor cells grown in pres-
ence of BM-MSC-CM compared to their levels in control cells grown in medium containing 10% FBS, which were arbitrarily determined to be 1.
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(Fig. 1B). Thus, BM-MSCs and factors released by BM-MSCs pro-
moted cell growth in U2OS and SNU-398 cells.
To investigate the mechanisms underlying the promotion of
tumor growth by BM-MSCs, we next analyzed the activation of cell
survival-related intracellular signals in the phosphatidyl-3-kinase
(PI3K)/Akt and extracellular signal-regulated kinase 1/2 (Erk1/2)
pathways. As shown in Fig. 1C, conditioned medium from BM-
MSCs increased P-Akt and P-Erk levels in both tumor cell lines
compared to the levels observed in cells grown in medium supple-
mented with 10% FBS (control), whereas no increase was observed
in Akt and Erk levels. We found that BM-MSC-CM caused a 2.54-
fold and a 2.44-fold increase in P-Akt levels in U2OS and SNU-398
cells, respectively, whereas P-Erk was increased by 1.3-fold in U2OS
and 1.9-fold in SNU-398 cells compared to the levels observed in
the controls (Fig. 1C).
BM-MSCs increase CXCR4 mRNA and protein expression in OS and
HCC cell lines
We analyzed whether the expression of chemokine receptor
type 4 (CXCR4), which is known to play a key role in cancer
metastasis, was affected by treatment with BM-MSC-CM. When
OS cells (U2OS and Saos-2) and HCC cells (SNU-398 and Hep3B)
were treated for 24 h with conditioned medium from BM-MSCs, a
signiﬁcant increase was observed in CXCR4 mRNA and protein
levels (Fig. 2).
Inhibiting CXCR4 prevents BM-MSCs-dependent wound healing in OS
and HCC cells
Because CXCR4 expression is correlated with tumor cell migra-
tion and metastatic potential [14], we investigated whether
conditioned medium from BM-MSCs would be able to affect wound
healing. Monolayers of U2OS and SNU-398 cells were scratched, and
images were taken at 0, 24 and 48 hours after wounding (Fig. 3A
and B). BM-MSC-CM caused a signiﬁcant increase in wound closure
in U2OS cells (64% and 82% at 24 h and 48 h, respectively) com-
pared to closure in the control cells (1% FBS) (P < 0.01). When U2OS
cells were grown in the presence of BM-MSC-CM and treated with
the CXCR4 antagonists AMD3100 (10 μM) or peptide R (10 μM),
wound healing was signiﬁcantly delayed compared to cells treated
with BM-MSC-CM alone (P < 0.001) (Fig. 3A). In SNU-398 cells, BM-
MSC-CM caused a signiﬁcant increase in wound closure (40% and
50% at 24 h and 48 h, respectively) compared to closure in control
cells, although this increase was lower than that observed for U2OS
cells. Both of the CXCR4 inhibitors, AMD3100 and peptide R, sig-
niﬁcantly reduced the wound closure induced by BM-MSC-CM
(P < 0.001) (Fig. 3B). To conﬁrm that inhibition of CXCR4 expres-
sion reduced the wound closure that was induced by BM-MSCs,
Saos-2 and Hep3B cells were transiently transfected with non-
targeting Scr siRNAs or CXCR4-speciﬁc siRNAs. A signiﬁcant reduction
was observed in CXCR4 levels in both cell lines when they were
transfected with CXCR4 siRNAs compared to cells transfected with
Scr siRNAs for 72 h (Supplementary Fig. S1A and B). Similar to what
was observed in U2OS and SNU-398 cells, we observed that Saos-2
and Hep3B cells that were treated with BM-MSC-CM showed
a signiﬁcant increase in wound closure compared to closure in the
control (1% FBS), whereas when these cells were treated with BM-
MSC-CM in the presence of the CXCR4 antagonists AMD3100 (10 μM)
or peptide R (10 μM), wound healing was signiﬁcantly delayed
(P < 0.001). Furthermore, when Saos-2 and Hep3B cells were trans-
fected with CXCR4-speciﬁc siRNAs, a signiﬁcant reduction was
observed in wound closure compared to closure in the cells trans-
fected with Scr siRNAs (P < 0.001) (Supplementary Fig. S1A and B).
Fig. 2. BM-MSCs increase CXCR4 mRNA and protein levels in OS and HCC cell lines. (A) Western blot analysis of CXCR4 expression in tumor cell lines after treatment with
BM-MSC-CM for 24 h. Actin was used as an equal loading control. The values below the blot indicate signal levels relative to controls, which were arbitrarily set to 1 (labeled
with asterisk). Representative data from one of three experiments are shown. (B) CXCR4 mRNA levels as detected using real-time PCR in OS and HCC cell lines grown for
24 h in the presence of BM-MSC-CM, medium with 1% FBS or medium with 10% FBS, as indicated.
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CXCR4 inhibitors prevent BM-MSC-dependent U2OS and SNU-398
cell invasion
We then examined the effect of BM-MSCs on the invasiveness
of U2OS and SNU-398 cells using trans-well chambers coated with
Matrigel. Fig. 4A and B demonstrate that a signiﬁcant increase was
observed in tumor cell invasiveness when either tumor cell line was
exposed to BM-MSC-CM or BM-MSCs (ratio 1:1), which was added
to the lower chamber as chemoattractant, compared to the inva-
siveness observed in the control cells (1% FBS used as the medium)
for 48 hours (P < 0.01). Inhibiting CXCR4 using AMD3100 or peptide
R dramatically suppressed the invasiveness of U2OS and SNU-398
cells that was promoted by BM-MSCs (P < 0.001). A similar inhib-
itory effect on BM-MSCs-induced invasiveness was observed on
Saos-2 and Hep3B cells when they were also cultured in the pres-
ence of AMD3100 or peptide R (Supplementary Fig. S2A and B).
CXCR4 inhibitors prevent BM-MSC-dependent ERK and AKT
activation and EMT in OS and HCC cell lines
To further characterize the involvement of the ERK and AKT path-
ways in BM-MSC-induced, CXCR4-mediated OS and HCC migration
and invasion, we analyzed P-Erk and P-Akt expression after cells were
treated with the CXCR4-speciﬁc antagonists AMD3100 and peptide
R and a speciﬁc CXCR7 antibody. Recent studies reported that CXCR7
expression is correlated with the CXCL12-CXCR4 axis during tumor
progression and furthermore that CXCR7 activates the same intra-
cellular signaling pathways activated by CXCR4 [32]. As shown in
Fig. 5, we observed a signiﬁcant reduction in P-Erk and P-Akt levels
when all cell lines that were grown in the presence of BM-MSC-
CM were treated with CXCR4 inhibitors, whereas a validated anti-
CXCR7 monoclonal antibody [33] was particularly effective in HCC
cell lines. The epithelial–mesenchymal transition (EMT) of tumor
cells is widely accepted to be closely correlated with cancer me-
tastasis. To explore whether CXCR4 promotes the EMT process in
OS and HCC cell lines grown in the presence of BM-MSC-CM, we
analyzed E-cadherin and vimentin levels after cells were treatedwith
AMD3100 and peptide R. We found that CXCR4 antagonists caused
an increase in E-cadherin and a reduction in vimentin levels in cells
that were grown in the presence of BM-MSC-CM (Fig. 6).
Discussion
Several studies have reported that BM-MSCs, which are known
to be involved in tissue homeostasis and regeneration, can be re-
cruited into primary tumors and become active components of the
tumor microenvironment, such as cancer-associated ﬁbroblasts
(CAFs) [34,35]. BM-MSCs contribute to tumor cell growth andmeta-
static behavior in a variety of cancers, including breast [8,36,37],
prostate [7,10,36], osteosarcoma [21–24] and colon [11,38,39] cancers.
In contrast, there is evidence showing that MSCs inhibit tumor pro-
gression [39]. In glioblastoma multiforme (GBM), BM-MSCs seem
to reduce tumor growth by inhibiting angiogenesis [40].
In the present study, we investigated the role of BM-MSCs in pro-
moting growth, migration and invasion in osteosarcoma and
hepatocellular carcinoma cell lines. Several previous studies have
reported that MSCs promoted the progression of different osteo-
sarcoma cell lines through different molecular pathways, including
Fig. 3. BM-MSCs induced an increase in wound healing in U2OS and SNU-398 tumor
cells that was inhibited by CXCR4 antagonists. (A) U2OS cells, after scratch wounds
were made using pipette tips, were grown for 24 and 48 hours in medium contain-
ing 1% FBS or 10% FBS or with conditioned medium obtained from cultured BM-
MSCs (BM-MSC-CM) in the presence of the CXCR4 inhibitors AMD3100 (10 μM) or
Peptide R (10 μM). (B) SNU-398 cells were tested in wound healing assays using the
same experimental conditions described above for U2OS cells. The distance between
the edges of the scratch was measured using ImageJ, the average distance was quan-
tiﬁed, and the extent of wound closure was determined as follows: wound closure
(%) = 1 − (wound width tx/wound width t0) × 100. All experiments were performed
at least three times. *P < 0.01 compared to the control (medium with 1% FBS);
#P < 0.001 compared to treatment with BM-MSC-CM.
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IL6/STAT3, CCL5 and CXCR4/VEGF [21–24], whereas few studies have
reported on the crosstalk between MSCs and hepatocellular carci-
noma cells [21–24]. The paracrine molecules secreted by MSCs can
act as ligands for receptors that are expressed on tumor cells, thereby
inducing the activation of the PI3K/Akt and Ras/ERK pathways, which
are involved in tumor cell progression [34]. We have shown that
conditioned medium obtained from BM-MSCs caused parallel in-
creases in osteosarcoma and hepatocellular carcinoma cell growth
and P-Akt/P-ERK levels, suggesting the activation of the PI3K/Akt
as well as the Ras/ERK intracellular cascades. Recently, it was shown
that MSCs are recruited into prostate tumors through CXCL16 and
that they are then converted in to cancer-associated ﬁbroblasts (CAFs)
[10]. In turn, CAFs secrete CXCL12, which binds to CXCR4 on tumor
cells to induce EMT, which ultimately promotes metastasis to sec-
ondary tumor sites [10]. Furthermore, it has been reported that BM-
MSCs may accelerate human breast tumor growth and metastasis
by regulating the cancer stem cell population through cytokine net-
works, the up-regulation of miR-199a and the repression of FOXP2
[6,41].
In summary, our ﬁndings indicate that BM-MSCs recruited into
the tumor stroma may promote osteosarcoma and hepatocellular
carcinoma growth by activating the PI3K/Akt and Ras/Erk path-
ways. Furthermore, we show that BM-MSCs may cause tumor cell
migration and invasion and the EMT phenotype through a process
that involves CXCR4 signaling. These mechanisms were impaired
by peptide R, a new CXCR4 antagonist. Future studies in animal
models will help to determine whether this is a viable strategy for
OS and HCC treatment.
In conclusion, this is the ﬁrst report to describe a new mole-
cule targeting CXCR4 for use as a potential therapeutic agent to
prevent the cancer progression and spreading that is regulated by
cross-talk between BM-MSCs and tumor cells.
Fig. 4. CXCR4 antagonists prevent BM-MSC-mediated U2OS and SNU-398 tumor cell invasion. Tumor cells were seeded into upper chambers containing 8 μm pore-size
ﬁlters that were coated with Matrigel basement membrane matrix in the presence or absence of the CXCR4 antagonists AMD3100 (10 μM) or Peptide R (10 μM). Medium
containing 1% FBS or 10% FBS, conditioned medium obtained from cultured BM-MSCs (BM-MSC-CM) or BM-MSCs were added to the lower chamber as a chemoattractant.
The invasiveness of U2OS cells and SNU-398 cells is described in panels A and B, respectively. All experiments were performed at least three times. *P < 0.001 compared to
the control (medium with 1% FBS); #P < 0.001 compared to BM-MSCs.
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Introduction
Members of the tumor necrosis factor (TNF) superfamily of 
cytokines bind to cognate receptors, called death receptors, 
on the surface of cells. Since their first discovery, more than 
20 human TNF ligands and more than 30 corresponding 
receptors have been identified.1 Members of this superfamily 
have a wide tissue distribution and regulate broad physiologi-
cal processes such as immune responses, hematopoiesis, 
morphogenesis, and cell death, thus playing a key role in 
homeostasis, up to their role in tumorigenesis.2 Key members 
of this family include TNF, CD95L (FasL), and TNF-related 
apoptosis-inducing ligand (TRAIL).
The clinical application of TNF ligands as cytotoxic agents 
for cancer is limited due to their toxicity. For example, TNF 
induces systemic toxicity.3 In vivo use of CD95L is also limited 
by its lethal hepatotoxicity resulting from massive hepatocyte 
apoptosis.4,5 TRAIL, instead, has been developed as a prom-
ising antitumor agent because it induces apoptosis in several 
tumor-derived cell types, but not in normal cells.6,7 However, 
tumors often develop resistance to TRAIL monotherapy. 
Resistance to drug treatment is mainly due to deregulation 
of apoptosis-related proteins such as PED, a death effector 
domain (DED) family member of 15 KDa having a variety of 
effects on cell growth and metabolism.8 PED has a broad 
anti-apoptotic function, being able to inhibit both the intrinsic 
and the extrinsic apoptotic pathways. In the extrinsic pathway, 
its interaction with Fas-associated protein with death domain 
(FADD) and pro-caspase-8 acts as competitive inhibitor of 
these pro-apoptotic molecules during the assembly of the 
death-inducing signaling complex (DISC).9–13 PED has been 
shown to be overexpressed in TRAIL-resistant human non-
small cell lung cancer (NSCLC) cells.14 An important mecha-
nism of protein expression regulation involves microRNAs 
(miRNAs).15,16 Toward this end, we found that miR-212 nega-
tively modulates PED expression and sensitizes NSCLC cells 
to TRAIL-induced apoptosis. In fact, miR-212 levels in resis-
tant cell lines of NSCLC were downregulated and inversely 
correlated with PED levels.17 Consistently, transfection of a 
miR-212 mimic resulted in sensitization of resistant cancer 
cells to TRAIL-induced apoptosis. This occurred, at least in 
part, through PED downregulation.17
A major obstacle to the translation of RNAi drugs (e.g., 
miRNA mimics) into the clinic is the absence of an effective 
targeted delivery system. In addition to their ability to inhibit 
the function of their targets, in the past decade much atten-
tion has been focused on aptamers as delivery vehicles for 
targeted therapy.18–20 Aptamers are highly structured single-
stranded RNA molecules that bind to their cognate molecu-
lar targets (including transmembrane receptors) with high 
affinity and selectivity.21,22 Aptamers have been successfully 
adapted for the targeted delivery of active molecules both 
in vitro and in vivo, including anticancer drugs, toxins, radio-
nuclides, siRNAs, and, more recently, miRNAs.23-25 Aptamer-
siRNA or aptamer-miRNA chimeras are characterized by low 
immunogenicity, easy chemical synthesis and modification, 
and superior target selectivity.23,26–28
In previous studies, an internalizing RNA aptamer 
(GL21.T)29 has been identified, through a cell-SELEX (sys-
tematic evolution of ligands by exponential enrichment) 
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TNF-related apoptosis-inducing ligand (TRAIL) is a promising antitumor agent for its remarkable ability to selectively induce 
apoptosis in cancer cells, without affecting the viability of healthy bystander cells. The TRAIL tumor suppressor pathway 
is deregulated in many human malignancies including lung cancer. In human non-small cell lung cancer (NSCLC) cells, 
sensitization to TRAIL therapy can be restored by increasing the expression levels of the tumor suppressor microRNA-212 (miR-
212) leading to inhibition of the anti-apoptotic protein PED/PEA-15 implicated in treatment resistance. In this study, we exploited 
a previously described RNA aptamer inhibitor of the tyrosine kinase receptor Axl (GL21.T) expressed on lung cancer cells, as 
a means to deliver miR-212 into human NSCLC cells expressing Axl. We demonstrate efficient delivery of miR-212 following 
conjugation of the miR to GL21.T (GL21.T-miR212 chimera). We show that the chimera downregulates PED and restores TRAIL-
mediate cytotoxicity in cancer cells. Importantly, treatment of Axl+ lung cancer cells with the chimera resulted in (i) an increase 
in caspase activation and (ii) a reduction of cell viability in combination with TRAIL therapy. In conclusion, we demonstrate that 
the GL21.T-miR212 chimera can be employed as an adjuvant to TRAIL therapy for the treatment of lung cancer.
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methodology.30 GL21.T aptamer is able to bind and inhibit 
the signaling of Axl receptor, belonging to the TAM family of 
tyrosine kinase receptors. Axl family members are activated 
by growth-arrest-specific gene 6 (GAS6), a member of the 
vitamin K–dependent protein family, that resembles blood 
coagulation factors rather than typical growth factors.31 Axl 
overexpression has been reported in many human cancers 
and is associated with invasiveness and/or metastasis in 
lung,32 prostate,33 breast,34 gastric,35 and pancreatic cancers,36 
renal cell carcinoma,37 as well as glioblastoma.38 Importantly, 
we have recently described the combinatorial potential of a 
chimera composed of GL21.T aptamer and a miRNA com-
bining the clinical benefits of both moieties.24 Here, we dem-
onstrate selective delivery of miR-212 to Axl+ lung cancer 
cells with GL21.T resulting in restoration of TRAIL-mediated 
sensitivity in NSCLC cells. Treatment of Axl+ cells with the 
GL21.T-miR212 chimera resulted in caspase activation and in 
a concomitant reduction of cancer cell viability. In conclusion, 
we describe a novel aptamer-miRNA chimera as a means to 
sensitize lung cancers to TRAIL therapy.
Results
Chimera design
To conjugate GL21.T aptamer and miR-212, a molecular chi-
mera (termed GL21.T-miR212) was designed using the RNA 
structure 5.3 program. GL21.T is a 34-mer truncated version 
of the original GL21 aptamer, corresponding to the functional 
portion of the aptamer able to bind to and to antagonize Axl 
receptor.29 GL21.T was used as a delivery carrier of human 
miR-212. For this purpose, the GL21.T sequence was elon-
gated at its 3′ end, by a covalent bond, with the sequence 
of the passenger strand of miR-212, and annealed to the 
guide strand. Even if full complementary miRNA sequences 
have been shown to be sufficient for targeted gene silenc-
ing,27,28 several recent reports on the use of molecular 
Figure 1 Chimeras structure prediction and binding and internalization analysis. Secondary structure prediction of chimeras using RNA 
structure 5.3 program. (a) GL21.T aptamer; (b) GL21.T-miR212; (c) GL21.Tscr-miR212. MiR mature sequence is indicated with an asterisk. 
(d) Internalization assay for the 5′-[32P]-labeled GL21.Tscr-miR212 and GL21.T-miR212 chimeras performed on A549 (Axl+) and MCF7 
(Axl−) cells. The percentage of the RNA internalized over bound was obtained subtracting the counts relative to the scrambled chimera  GL21.
Tscr-miR212 used as negative control. Each bar shows the mean ± SD values from three wells. (e) Internalization analysis of GL21.T,  GL21.
Tscr-miR212, and GL21.T-miR212 was monitored using quantitative RT-PCR (qRT-PCR) and normalizing to an internal RNA reference control 
for the PCR. The percentage of internalization has been expressed as the amount of internalized RNA relative to total bound RNA. Statistics 
were calculated using Student’s t-test, ****p < 0.0001; ***p < 0.001. Each bar shows the mean ± SEM values from three wells.
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aptamer-siRNA chimeras have shown that silencing efficacy 
and specificity can be improved by introducing internal par-
tial complementarities and increased length extension with 
respect to the mature sequence in order to obtain a more 
effective Dicer substrate.26,39,40 Therefore, in order to encour-
age correct strand selection and thereby encourage target 
specificity, passenger and guide strands presented an imper-
fect pairing, consisting in a portion of stem-loop structure 
making the double strand similar to the pre-miR. A scrambled 
chimera, GL21.Tscr-miR212, was also designed, with the 
GL21.T sequence substituted by an unrelated sequence of 
the same length elongated with the miR-212 mimic passen-
ger strand and annealed to the full complementary miR-212 
guide strand. In both types of chimera, the antisense strand 
presented two overhanging bases (UU) at 3′ end necessary 
for Dicer processing (Figure 1). Since, based on its predicted 
structure, the folding of GL21.T appears to be preserved also 
in the context of the chimera, we experimentally assessed 
the selective binding and the internalization potential of 
GL21.T-miR212 on Axl-expressing cells. Binding and inter-
nalization assays were performed using A549 (Axl+) cells, 
while MCF7 cells were used as negative control since they 
do not express Axl. As shown in Figure 1, GL21.T-miR212 
was able to bind to and internalize into A549 respect to the 
scrambled chimera used as control, but not in MCF7 cells, 
as assessed by two different methods (Figure 1d,e). Note-
worthy, a similar percentage of internalization was obtained 
 comparing GL21.T-miR212 and GL21.T alone (Figure 1e). 
These results indicate that, as previously reported for the 
GL21.T aptamer,29 in the GL21.T-miR212 conjugate, the 
binding specificity of the GL21.T aptamer moiety is pre-
served and the conjugate is internalized into target cells in a 
receptor-dependent manner.
Dose–response effects and dicer processing of GL21. 
T-miR212 chimera
In order to characterize the effects of the chimera treatment 
on the miR-212 target, PED protein, A549 cells were treated 
with increasing amounts of GL21.T-miR212 and of control, 
GL21.Tscr-miR212, for 48 hours (Figure 2a). By western 
blot, we observed that PED levels were reduced in a dose–
response manner by a concentration of 200 nM.
To test the specificity of the GL21.T-miR212 chimera and 
simultaneously evaluate the broad applicability of our delivery 
Figure 2 MiR-212 effect, aptamer-mediated specific delivery, and Dicer processing of GL21.T-miR212 chimera. (a) A549 cells 
were treated with different final concentrations (50, 100, 200, and 300 nM) of chimera and scrambled chimera for 48 hours. (b) A549 cells 
were incubated with GL21.T-miR340, GL21.T, and GL21.T-miR212 or alternatively were transfected with pre-miR-212 and pre-miR-340. 
(c) A549 cells were transfected with the aptamer alone, GL21.Tscr-miR212 and GL21.T-miR212. (d) A549 cells were transfected with control 
scrambled or  pre-miR-212 or treated with the aptamer alone or GL21.T-miR212 in presence or absence of Dicer-siRNA. After 48 hours, the 
efficiency of si-Dicer transfection (left panel) was controlled by immunoblotting using anti-Dicer and anti-α-tubulin antibodies. The effect on 
the downregulation of target protein (right panel) was analyzed by immunoblotting with anti-PED and anti-β actin antibodies. Values below 
the blots indicate signal levels relative to (a) scrambled chimera-treated cells, arbitrarily set to 1 (with a different number of asterisks for each 
dose), or (b,d) to untreated cells (indicated as “WT”), and (c) to GL21.T-treated cells arbitrarily set to 1 (with asterisk). Intensity of bands was 
calculated using ImageJ (v1.46r). For a, b, and c, cell lysates were immunoblotted with anti-PED and anti-β actin antibodies.
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platform, we conjugated the Axl aptamer to a different miR, 
miR-340. We have recently described that miR-340 has an 
onco-suppressive role in NSCLC by targeting PUM1, PUM2, 
and SKP2. The downregulation of these three genes was 
inversely correlated to p27 expression.41 Treatment of A549 
cells with GL21.T-miR340 resulted in an increase in miR-340 
expression levels suggesting the proper internalization of the 
chimera. The effect on SKP2 downregulation, as well as on 
the increase of p27 levels, confirmed the effectiveness of the 
conjugate (Supplementary Figure S1). This effect was simi-
lar to that observed with transfection of A549 cells with miR-
340 (used as positive control). In contrast, as anticipated, 
the aptamer alone and the aptamer conjugated to miR-340 
(GL21.T-miR340) did not reduce PED protein levels under 
the same experimental conditions. By western blot, results 
showed that GL21.T-miR340 was not able to modify PED 
levels, thus indicating that PED downregulation was merely 
dependent on miR-212 moiety (Figure 2b).
To demonstrate that GL21.Tscr-miR212 was not functional 
due to the aptamer portion and not to inactivation of the miR 
sequence, A549 cells were transfected with the aptamer 
alone, GL21.Tscr-miR212 and GL21.T-miR212. As shown, 
following transfection, the scrambled chimera was as effec-
tive as the GL21.T-miR212 at downregulating PED protein 
levels (Figure 2c).
In order to investigate the mechanism by which the chimera 
was functional, A549 cells were transfected with a Dicer-specific 
siRNA and, then, treated with GL21.T-miR212. The co-transfec-
tion of pre-miR-212 was used as positive control. The efficiency 
of si-Dicer transfection and the effect on the downregulation of 
target protein were determined by immunoblotting (Figure 2d). 
As shown, in the presence of a Dicer-specific siRNA, GL21.T-
miR212 was not able to reduce PED protein level, suggesting 
that Dicer was necessary for chimera processing.
Cell-type specificity of chimera treatment
To test whether PED downregulation was cell-type specific, 
A549 (Axl+) and MCF7 (Axl-) cells were treated with GL21. 
T-miR212 and GL21.Tscr-miR212. Transfection of pre-
miR-212 and treatment with GL21.T aptamer were used as 
positive and negative controls, respectively. In A549 cells, 
GL21.T-miR212 downregulated PED both at mRNA level 
(measured using qRT-PCR) and protein level (assessed by 
immunoblotting with specific antibodies). As expected, no 
effect of the chimeras on PED expression was observed in 
MCF7 (Axl-negative) cells (Figure 3a,b). To confirm that the 
effects on PED protein levels were mediated by miR-212 
upregulation, the same samples were evaluated by qRT-PCR 
to analyze miR-212 expression (Figure 3c). GL21.T deliv-
ered miR-212 inside the target cells, resulting in miR-212 
Figure 3 Cell-type specificity of chimera treatment. (a) A549 and MCF7 cells were treated with 300 nM of GL21.T-miR212 for 48 hours. 
GL21.Tscr-miR212 and GL21.T aptamer were used as negative controls, whereas transfection with 100 nM of pre-miR-212 was used as 
positive control. Control scrambled was used to assure transfection efficiency. Cell lysates were immunoblotted with anti-PED and anti-β actin 
antibodies for PED protein levels while (b) PED expression levels were analyzed by qRT-PCR. (c) The same samples were subjected to  qRT-
PCR for miR-212 expression levels analysis. Bands’ intensity has been calculated as in Figure 2. In b and c each bar shows the mean ± SD 
values from three wells. Statistics were calculated using Student’s t-test, ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05.
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upregulation. Furthermore, despite the fact that the intra-
cellular levels of miR-212 were lower in cells treated (no 
transfection reagent used) with GL21.T-miR212 compared 
with cells transfected with the pre-miR, the effects on PED 
downregulation were comparable. Results indicate that the 
efficiency of the conjugate to deliver functional miR-212 and 
thus modulate the expression of miRNA target genes is simi-
lar to that observed with transfection. We also validated the 
effect of GL21.T-miR212 on PED downregulation in other 
NSCLC Axl+ cell lines, Calu-1 and HCC827-ER3 (Figure 4).
Receptor-dependent internalization of GL21.T-miR212 
chimera
To confirm receptor-dependent internalization of GL21. 
T-miR212 chimera, we silenced Axl  levels in A549 cells 
with RNAi. Following 48 hours of si-Axl  transfection, we 
tested the binding and internalization potential of GL21. 
T-miR212. As expected, we observed a statistically signifi-
cant decrease in bound/internalized GL21.T aptamer and 
chimera in A549 (siAxl)-treated cells. In contrast, no dif-
ferences in binding/internalization were observed for the 
scrambled chimera (Figure 5a). The efficiency of si-Axl 
transfection and the effect on the downregulation of target 
protein were determined by immunoblotting (Figure 5b). 
Alternatively, Axl  levels were transiently upregulated 
transfecting Axl  cDNA. Following Axl  overexpression, the 
treatment with GL21.T-miR212 increased miR-212 levels 
by twofold compared with parental A549. Simultaneously, 
the conjugate decreased PED levels to the same extent in 
parental and transfected A549 cells (Figure 5c). Thus, we 
conclude that the functional delivery of miR-212 is depen-
dent on the amount of Axl on the cell surface and that the 
additional miR-212 delivered is not necessary to increase 
the effect on PED downregulation. We next assessed 
whether internalization of the conjugate was Axl mediated. 
MCF7 cells were transiently transfected with Axl cDNA 
and levels of miR-212 evaluated following treatment with 
the conjugate. As predicted, miR-212 levels were higher in 
cells treated with GL21.T-miR212, compared with the treat-
ment with GL21.Tscr-miR212 or the aptamer alone, thus 
indicating that internalization of GL21.T-miR212 chimera is 
receptor dependent (Supplementary Figure S2).
Figure 4 Effects of GL21.T-miR212 on additional Axl+ non-small cell lung cancer (NSCLC) cell lines. (a,d) Calu-1 and HCC827-ER3 
cells were treated with 300 nM of GL21.T-miR212, GL21.Tscr-miR212, and GL21.T aptamer or, alternatively, transfected with 100 nM of  pre-
miR-212. After 72 hours for Calu-1 or 48 hours for HCC827-ER3, cells were collected and cell lysates were immunoblotted with anti-PED and 
anti-β actin antibodies for PED protein levels. (b) The same samples of HCC827-ER3 were subjected to qRT-PCR for miR-212 and (c) for 
PED expression levels analysis. In a,d values below the blots indicate signal levels relative to untreated cells (indicated as “WT”), arbitrarily 
set to 1 (with asterisk). Bands’ intensity has been calculated as in Figure 2. In b and c each bar shows the mean ± SD values from three wells. 
Statistics were calculated using Student’s t-test, ****p < 0.0001; ***p < 0.001; *p < 0.05.
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GL21.T-miR212 regulates TRAIL-induced cell death
We have previously shown that the TRAIL-resistant pheno-
type in NSCLC is related to aberrant elevated levels of PED. 
Furthermore, we showed that ectopic expression of miR-
212 (achieved with a miR mimic) downregulates PED and 
re-establishes sensitivity to TRAIL.14,17 To investigate whether 
treatment with the chimera induced sensitivity to TRAIL, we 
treated A549 cells with GL21.T-miR212. GL21.Tscr-miR212 
and transfected pre-miR-212 were included as negative and 
positive controls, respectively. Caspase-8 activation was 
evaluated following treatment with TRAIL for 3 hours by west-
ern blot (Figure 6a). As shown, cleavage of caspase-8 was 
evident in cells treated with GL21.T-miR212 or, alternatively, 
transfected with pre-miR-212, but not with the GL21.Tscr-
miR212, and accompanied by the activation of caspase 3/7, 
assessed by Caspase-Glo® 3/7 Assay (Figure 6b). Thus, 
sensitization to TRAIL upon treatment with the chimera was 
selective for Axl-expressing cells as demonstrated by the 
activation of caspase 3/7. To further confirm that the chimera 
sensitizes cancer cells to TRAIL-induced apoptosis, we eval-
uated the percentage of apoptotic cells after TRAIL treatment 
(Figure 7a). Transfected or treated cells were labeled with 
Annexin V-FITC and propidium iodide and analyzed using 
flow cytometry. GL21.T-miR212 increased the percentage of 
apoptotic (Annexin V—positive, PI—negative) cells following 
TRAIL treatment, as miR-212 was used as positive control. 
In addition, we measured cell viability using an MTT assay 
that showed the same results (Figure 7b). GL21.T-miR340 
treatment did not produce any gain in TRAIL sensitivity 
 (Figure 7c). In summary, the GL21.T-miR212 chimera was 
able to increase the activation of caspase3/7 and, conse-
quently, TRAIL-induced cell death in A549 cells, but not in 
MCF7 cells. TRAIL sensitization mediated by GL21.T-miR212 
treatment was also confirmed on additional NSCLC cell lines, 
Calu-1 and HCC827-ER3, which display a TRAIL-resistant 
phenotype (Figure 8).
Discussion
NSCLC represents about 80% of all lung cancers and is 
mostly diagnosed at an advanced stage (either locally 
advanced or metastatic disease). Because of resistance 
to therapeutic drugs, standard treatment of this tumor has 
Figure 5 Receptor-dependent internalization of GL21.T-miR212 chimera. (a) A549 cells were transfected with si-Axl or siRNA control for 
24 hours and, then, treated with GL21.T-miR212, the scrambled chimera or with the aptamer alone to perform the binding (upper panel) and 
internalization (lower panel) assays. Each bar shows the mean ± SEM values from three wells. (b) The efficiency of si-Axl transfection and 
the effect on the downregulation of target protein were evaluated after 48 hours of treatment by immunoblotting with anti-Axl and anti-tubulin, 
in the upper panel, and with anti-PED and anti-β actin antibodies, in the lower panel. Values below the blots indicate signal levels relative to 
untreated cells (indicated as “WT”), arbitrarily set to 1 (with asterisk). Bands’ intensity has been calculated as in Figure 2. (c) A549 (Axl+) 
cells, following 24-hour transfection with Axl TruClone (Axl), were treated with 300 nM of GL21.T-miR212, GL21.Tscr-miR212, or GL21.T for 
additional 48 hours. miR-212 (upper panel), PED and Axl (lower panel) levels were quantified by RT-qPCR. Each bar shows the mean ± SD 
values from three wells. Statistics were calculated using Student’s t-test, ****p < 0.0001; **p < 0.01.
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only a 20% to 30% positive clinical response. Over the last 
years, the discovery of the pivotal of epidermal growth fac-
tor receptor (EGFR) in tumorigenesis has opened the way to 
a new class of targeted therapeutic agents: the EGFR tyro-
sine kinase inhibitors (EGFR TKIs). Since their introduction 
in therapy, in advanced NSCLC patients harboring EGFR 
mutations, the use of EGFR TKIs in first-line treatment has 
provided an unusually large progression-free survival ben-
efit with a negligible toxicity when compared with cytotoxic 
chemotherapy. Nevertheless, resistance invariably occurs.42 
In this setting, TRAIL emerged as a novel therapeutic agent. 
TRAIL (ApoL/TNF-related apoptosis-inducing ligand) is a rel-
atively new member of the tumor necrosis factor (TNF) ligand 
family, which induces apoptosis in a variety of cancers.
Initial promising studies demonstrated its remarkable speci-
ficity in inducing apoptosis in tumor cell lines, but not in nor-
mal cells both in vitro and in vivo.7 This unique property makes 
TRAIL an attractive candidate for targeted cancer therapy.43,44 
However, resistance to TRAIL-induced apoptosis poses a 
challenge for effective anticancer strategies. To overcome this 
problem, drug cocktails in combination with TRAIL therapy 
have been proposed in order to induce synergism or sensitize 
resistant cancer cells. Toward this end, a number of combinato-
rial treatments with chemotherapeutic agents are in phase 1/2 
of clinical studies.45–47 More recently, aptamer-siRNA/miRNA 
chimeras have been proposed as novel adjuvants to standard 
chemotherapy.48,49 Unlike nontargeted drugs, the advantage of 
these new class of biodrugs is that they are specifically deliv-
ered into target cells where they release their therapeutic cargo, 
thus limiting toxicity to normal cells.
In this study, we designed a chimera composed of a RNA 
aptamer to Axl (GL21.T) and miR-212 as a means to deliver 
functional miR-212 into TRAIL-resistant Axl+ A549 cells, but 
not into Axl- MCF7 cells. Indeed, GL21.T-miR212 selectively 
sensitizes the A549 cells to TRAIL-induced apoptosis, prov-
ing to be a unique tool to synergize with TRAIL in mediating 
cell death.
To increase specificity and facilitate large-scale chemical 
synthesis,24,26,50 we conjugated a truncated version of the GL21 
aptamer (GL21.T) to the tumor suppressor miR-212 duplex 
sequence. We demonstrated that in the context of the chimera, 
the active sequence (sequence required for binding to Axl) of 
GL21 is preserved, thus providing high binding affinity and the 
subsequent selective internalization of the conjugate into Axl+ 
cells. The miRNA moiety is a 25/27mer duplex having two over-
hanging bases (UU) at the 3′ end of the passenger strand, thus 
adopting the conformation described as Dicer substrate for 
duplex siRNAs.51 By using a similar approach with miRNAs, we 
have recently shown that nonperfect duplex miRNAs are cor-
rectly processed by Dicer, increasing the gene target specificity 
of the miRNA moiety.24 Indeed, the optimal loading of the guide 
strand into RNA-induced silencing complex (RISC) is thought 
to reduce off-target effects that result from inappropriate incor-
poration of both miRNA strands into the silencing complex.52
A major limitation to the use of RNA-based drugs in vivo is 
the rapid degradation (within few minutes) of natural RNAs in 
serum or blood. As previously described, in order to protect the 
GL21.T aptamer from degradation, it was generated as a 2′-F-
Py containing RNA.29 Therefore, in order to increase the stabil-
ity of the entire GL21.T-miR212 molecule, we substituted the 
Figure 6 Caspases activation induced by GL21.T-miR212. (a) A549 cells were transfected with 100 nM of pre-miR-212 or alternatively 
treated with 300 nM of GL21.T-miR212 for 48 hours. Scrambled miR and scrambled chimera were used as negative controls. Cells were, then, 
treated for 3 hours with TNF-related apoptosis-inducing ligand (TRAIL) 50 ng/ml, and cell lysates were immunoblotted with anti-caspase-8 
antibody (upper panel). Band intensity is represented in the diagram of the lower panel as a ratio of cleaved over total caspase-8, both 
quantization normalized over β-actin. (b) A549 and MCF7 cells were transfected with pre-miR-212 or treated with the unconjugated aptamer, 
the scrambled chimera and GL21.T-miR212 for 48 hours and then incubated with 50 ng/ml of TRAIL for 6 hours. The activation of caspase 3/7 
was measured by Caspase-Glo® 3/7 Assay. Each bar shows the mean ± SD values from three wells. Statistics were calculated using Student’s 
t-test, ****p < 0.0001; ***p < 0.001; **p < 0.01.
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pyrimidines with 2′-F-Py at all positions. This modification is well 
characterized in humans and is reported to be well tolerated 
with little toxicity.53 RNA aptamers with this modification have 
already been approved for their use in humans (Macugen), 
with many more quickly moving through the clinical pipeline.54 
Although we cannot completely rule out potential intracellular 
toxicity of 2′-F-Py-modified RNAs leading to nonspecific immu-
nostimulation, experiments in vivo demonstrated that problem-
atic toxicity in humans is not expected.24,26
The silencing moiety of the chimera is constituted by the 
miR-212, a tumor suppressor miRNA that acts by negatively 
modulating PED expression, an onco-protein with a broad 
anti-apoptotic action. Indeed, the presence of elevated cel-
lular levels of PED has been shown to contribute to resis-
tance to TRAIL-induced cell death in several human tumors, 
including breast and lung cancer.17,55 The DED domain of 
PED acts as a competitive inhibitor for pro-apoptotic mole-
cules during the assembly of a functional DISC and inhibiting 
the activation of caspase-8, which take place following treat-
ment with different apoptotic cytokines (CD95/FasL, TNF-α, 
and TRAIL). These data demonstrate that GL21.T-miR212 is 
a functional molecule that upon internalization, downregu-
lates PED in a dose-dependent manner, reaching a plateau 
at around 200 nM. In turn, target cells become sensitive to 
TRAIL and upon treatment undergo apoptosis following cas-
pase-8 and caspase-3 activation.
Based on the suppressive action of miR-212 on PED 
expression as a means to sensitize cancer cells to TRAIL, 
here we demonstrated that GL21.T-miR212 chimera can 
sensitize target cells in a high selective manner. Specifically, 
exogenous miR-212 delivered by GL21.T aptamer led to 
TRAIL sensitization via activation of the apoptotic cascade 
selectively in A549, NSCLC Axl+ cells. In conclusion, the 
approach presented in this work indicates an innovative tool 
for a combined therapy that makes use of an aptamer-based 
molecular chimera to selectively sensitize TRAIL-resistant 
target tumor cells.
Materials and methods
Cell lines and transfection. A549 and HCC827-ER3 cells 
were grown in RPMI 1640 while MCF7 and Calu-1 cells were 
grown in Dulbecco's modified Eagle's medium. A549, MCF7, 
and Calu cells were from American Type Culture Collection, 
while HCC827-ER3 were kindly provided by Dr. Balazs Hal-
mos (Columbia University Medical Center, New York, NY). 
Their media were supplemented with 10% heat-inactivated 
fetal bovine serum, 2 mM of glutamine, and 100 U/ml of peni-
cillin/streptomycin. For miRNAs transient transfection, cells 
were transfected with 100 nM (final concentration) of miRNA 
stem-loop precursor hsa-miR212, hsa-miR340, or negative 
control 1 (Ambion, Foster City, CA) using Oligofectamine (Invi-
trogen, Carlsbad, CA). Also si-control and si-Axl (Santa Cruz 
Biotechnology, Santa Cruz, CA) were transfected using Oligo-
fectamine (Invitrogen), according to the manufacturer’s proto-
col. For aptamer and chimeras transient transfection, cells were 
transfected with 100 nM (final concentration) of RNAs, using 
Lipofectamine 2000 (Invitrogen). Also Axl TruClone (Origene, 
Rockville, MD) and si-Dicer (Cell Signaling Technology, Beverly, 
MA) were transfected with Lipofectamine 2000, according to 
the manufacturer’s protocol.
Aptamer-miRNA chimeras. The following sequences were used 
for the chimera production: GL21.T-miR212 passenger strand: 
Figure 7 TNF-related apoptosis-inducing ligand (TRAIL) 
sensitization induced by GL21.T-miR212. (a) A549 cells were 
transfected with pre-miR-212 and control scrambled or treated 
with the chimera, the scrambled chimera and the unconjugated 
aptamer for 48 hours. Cells were, then, incubated with TRAIL for 24 
hours, and the percentage of apoptotic cells was evaluated by flow 
cytometry. (b) A549 and MCF7 cells were treated with 300 nM of 
GL21.T-miR212 and GL21.Tscr-miR for 48 hours and were exposed 
to TRAIL for 24 hours at 50 ng/ml as final concentration. (c) A549 
cells were treated with the unconjugated aptamer, GL21.T-miR212 
or GL21.T-miR340 for 48 hours and were exposed to TRAIL for 24 
hours at 50 ng/ml as final concentration. For b and c cell viability 
was evaluated with MTT assay. In a, b, and c each bar shows the 
mean ± SD values from three wells. Statistics were calculated using 
Student’s t-test, ****p < 0.0001; **p < 0.01.
Transf. Treated
TRAIL 50 ng/ml
WT GL21.Tscr-miR212 GL21.T-miR212
A549
A549
NT
TRAL 50 ng/ml
MCF7
100
Ce
ll v
ia
bi
lity
 %
 o
ve
r u
nt
re
at
ed
15
10
5
0P
er
ce
nt
 o
f a
po
pt
ot
ic 
ce
lls
80
60
40
20
0
100
Ce
ll v
ia
bi
lity
 %
 o
ve
r u
nt
re
at
ed
80
60
40
20
0
****
****
**
TRAIL 50 ng/ml
****
W
T
sc
r
GL
21
.T
m
iR
-21
2
GL
21
.T-
m
iR
21
2
GL
21
.Ts
cr-
mi
R2
12
W
T
GL
21
.T
GL
21
.T-
m
iR
34
0
GL
21
.T-
m
iR
21
2
a
b
c
www.moleculartherapy.org/mtna
Aptamer and Cancer Therapy
Iaboni et al.
9
5 ′GGGAUGAUCAAUCGCCUCAAUUCGACAGGAGG 
CUCACGGUACCUUGGCUCUAGACUGCUUACUUU. miR- 
212 guide strand: 5′ AGUAACAGUCUCCAGUCACGGCC 
ACC. GL21.Tscr-miR212 passenger strand: 5′GGGUUCGU 
ACCGGGUAGGUUGGCUUGCACAUAGAACGUGUCAGG 
CCGUGACUGGAGACUGUUAUU. miR-212 (1g) guide 
strand: 5′ UAACAGUCUCCAGUCACGGCC. GL21.T: 5′ GGG 
AUGAUCAAUCGCCUCAAUUCGACAGGAGGCUCAC. 
GL21.T-miR340 passenger strand: 5′GGGAUGAUCAAUCG 
CCUCAAUUCGACAGGAGGCUCACAAUCAGUCUCA 
UUGCUUUAUAAUU. miR-340 guide strand: 5′ UUAUAAA 
GCAAUGAGACUGAUU.
All RNAs were custom synthesized by TriLink Biotechnolo-
gies (San Diego, CA) as 2′-fluoropyrimidine RNAs. UU in 
bold are 3′-overhang. The control conjugate is composed of 
an unrelated aptamer sequence linked to the fully comple-
mentary miR-212 duplex. In the context of the control conju-
gate, it was necessary to use a fully complementary miR-212 
to stabilize the functional miR duplex and prevent unwanted 
intramolecular interactions with the scrambled aptamer 
sequence.
To prepare GL21.T-miR212, GL21.Tscr-miR212, and 
GL21.T-miR340, 5 µM of aptamer-passenger RNA strand 
was denatured at 98 °C for 20 minutes, combined with 5 µM 
of the appropriate guide strand at 55 °C for 10 minutes in 
binding buffer 10× (200 mM N-2-Hydroxyethylpiperazine-N'-
2-Ethanesulfonic Acid, pH 7.4, 1.5 M NaCl, 20 mM CaCl2) and 
then warmed up to 37 °C for 20 minutes.
Cell binding and internalization assays. Aptamer binding and 
internalization have been assessed by two different methods, 
by radioactivity labeling or by quantitative reverse transcrip-
tion-PCR (qRT-PCR)
Radioactivity labeling. A549 and MCF7 cells were plated in 24 
multiwell plates in triplicate. RNAs were 5′-[32P]-labeled and 
incubated at 200 nM as final concentration on cells at 37 °C for 
15 minutes. After several washings, the amount of 32P-labeled 
RNA recovered in SDS 1% was determined by scintillation 
counting. In contrast, to check the endocytosis rate, after the 
incubation with radiolabeled chimeras, the cells were subjected 
to a stringent high-salt wash, with High Salt phosphate-buffered 
saline (PBS; 0.5 M NaCl), to remove any unbound RNAs or 
RNAs bound to the cell surface. Following 5-minute treatment 
at 4 °C, the amount of 32P-labeled RNA internalized was recov-
ered in Sodium Dodecyl Sulfate  1% and determined by scintil-
lation counting. In both assays, results were normalized for cell 
Figure 8. TNF-related apoptosis-inducing ligand (TRAIL) sensitization induced by GL21.T-miR212 in additional Axl+ non-small cell 
lung cancer (NSCLC) cell lines. Calu-1 and HCC827-ER3 cells were transfected with pre-miR-212 or treated with the unconjugated 
aptamer, the scrambled chimera and GL21.T-miR212. (a,b) After 72 hours for Calu-1 or 48 hours for HCC827-ER3 of treatment or 
transfection, cells were incubated with TRAIL (100 ng/ml in Calu-1 and 50 ng/ml in HCC827-ER3) for 6 hours. The activation of caspase 3/7 
was measured by Caspase-Glo® 3/7 Assay. (c) The same samples of HCC827-ER3 were exposed to TRAIL for 24 hours, and cell viability 
was evaluated with MTT assay. Each bar shows the mean ± SD values from three wells. Statistics were calculated using Student’s t-test, 
****p < 0.0001; ***p < 0.001; *p < 0.05.
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number. The background values obtained with the scrambled 
chimera were subtracted from the values obtained with GL21.T-
miR212. Finally, the resulting recovered RNAs were plotted as 
percent of RNA internalized over RNA bound.
qRT-PCR method. Target (A549) and nontarget (MCF7) cells 
were incubated with 100 nM of aptamer or chimeras for 15 
minutes at 37 °C with 5% CO2. Cells were washed with ice-
cold PBS or incubated with High Salt PBS (0.5 M NaCl) at 
4 °C for 5 minutes, and RNA was recovered using TRIzol 
reagent (Invitrogen). Samples were normalized to an inter-
nal RNA reference control. Specifically, 0.5 pmol per sample 
CL4 aptamer56 was added to each sample along with TRIzol 
as a reference control. Recovered RNAs were quantitated 
using Reverse Transcriptase M-MuLV (Roche Life Science, 
Basel, Switzerland) with SYBR Green (BioRad) with a Biorad 
iCycler. All reactions were done in a 25-ml volume in trip-
licate with specific primers (GL21.T 5′: TAATACGACTCAC-
TATAGGGATGATC; 3′: GTGAGCCTCCTGTcGAAT; GL21.
Tscr 5′: TTCGTACCGGGTAGGTT; 3′: TGACACGTTCTAT-
GTGCA) and CL4 reference control (CL4 5′: TAATACGACT-
CACTATAGGGGCCTTA; 3′: GCCTCCTGTCGAATCG).
For each cell line, the percentage of internalization has 
been expressed as the amount of internalized RNA relative 
to total bound RNA without normalizing for background. The 
same protocol was used for the experiment on A549 cells 
upon transfection with si-control and si-AXL.
Protein isolation and immunoblotting. Cells were treated with 
chimeras for 48 hours, or alternatively Calu-1 for 72 hours, and 
then were washed twice in ice-cold PBS and lysed in Lysis buf-
fer (50 mM N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic 
Acid pH 7.5 containing 150 mM NaCl, 1% GLYCEROL, 1% 
Triton 100×, 1.5 mM MgCl2, 5 mM ethylene glycol tetraacetic 
acid, 1 mM Na3VO4 and 1X protease inhibitor cocktail). Protein 
concentration was determined by the Bradford assay (Bio-
Rad, Hercules, CA) using bovine serum albumin as the stan-
dard, and equal amounts of protein were analyzed by Sodium 
Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (15% 
acrylamide). Gels were electroblotted onto nitrocellulose mem-
brane (Merck Millipore, Billerica, MA). For immunoblot experi-
ments, membranes were blocked for 1 hour with 5% non-fat 
dry milk in tris-buffered saline containing 0.1% Tween-20 and 
incubated at 4 °C overnight with primary antibody. Detection 
was performed by peroxidase-conjugated secondary anti-
bodies using the enhanced chemiluminescence system (GE 
Healthcare Life Sciences, Pittsburgh, PA). Primary antibodies 
used were anti-PED,57 anti-Caspase-8, anti-p27, and anti-Dicer 
from Cell Signaling Technology, anti-α tubulin from Santa Cruz 
Biotechnology, anti-β actin from Sigma-Aldrich (St. Louis, MO), 
and anti-Axl from R&D Systems (Minneapolis, MN).
RNA extraction and Real-time PCR. Cells were treated with 
300 nM of chimeras for 48 hours, and then total RNAs (miRNA 
and mRNA) were extracted using TRIzol (Invitrogen) accord-
ing to the manufacturer’s protocol. Reverse transcription of 
total miRNA was performed starting from equal amounts of 
total RNA/sample (1 µg) using miScript reverse Transcription 
Kit (Qiagen, Hilden, Germany). Quantitative analysis of miR-
NAs and RNU6B (as an internal reference) was performed by 
real-time PCR using specific primers (Qiagen) and miScript 
SYBR Green PCR Kit (Qiagen). The reaction for detection 
of miRNAs was performed as follows: 95 °C for 15 minutes, 
40 cycles of 94 °C for 15 seconds, 55 °C for 30 seconds, 
and 70 °C for 30 seconds. All reactions were run in triplicate. 
For reverse transcription of mRNA, we used SuperScript® 
III Reverse Transcriptase (Life Technologies). Quantitative 
analysis of PED, AXL, and actin (as an internal reference) 
was performed by real-time PCR using specific primers and 
iQTM SYBR Green Supermix (BioRad). The threshold cycle 
(CT) is defined as the fractional cycle number at which the 
fluorescence passes the fixed threshold. For quantization 
has been used the 2(-ΔCT) method, where ΔCt is the differ-
ence between the amplification fluorescent thresholds of the 
miRNA of interest and the miRNA of U6 used as an internal 
reference. Instead, fold changes were calculated with 2(-ΔΔCT) 
method as previously described.58 Experiments were carried 
out in triplicate for each data point, and data analysis was 
performed by using software (Bio-Rad).
Cell death quantification. A549, MCF7, and HCC827-ER3 cells 
were treated with GL21.T-miR212 and GL21.Tscr-miR212 
300 nM for 3 hours. Then, cells were plated in 96 multiwell 
plates in triplicate for 48 hours and incubated with TRAIL (Vinci-
Biochem, Firenze, Italy) at a final concentration of 50 ng/ml for 
24 hours. Cell viability was assessed with CellTiter 96 Aque-
ous One Solution Cell Proliferation Assay (Promega, Madison, 
WI). Metabolically active cells were detected by adding 20 µl 
of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) to each well, and plates were 
analyzed in a Multilabel Counter (BioTek, Winooski, VT).
Caspase 3/7 assay. The assay was performed with the use of 
Caspase-Glo ® 3/7 Assay (Promega) according to the manu-
facturer’s protocol. Briefly, A549, MCF7, and HCC827-ER3 
cells were before transfected with pre-miR-212 or treated with 
GL21.T, GL21.Tscr-miR212, GL21.T-miR212 for 48 hours, or 
alternatively Calu-1 for 72 hours, and, then, incubated for 6 
hours with TRAIL. An equal volume of Caspase-Glo 3/7 reagent 
was added to each well for 30 minutes in the dark, and lumi-
nescence was measured by luminometer (Turner BioSystems-
Promega). The ratio of caspase 3/7 activity over control was 
calculated normalizing treated samples over untreated ones.
Flow cytometry. Apoptosis was analyzed via Annexin V-FITC 
Apoptosis Detection kit I (BD Biosciences, San Diego, CA). 
A549 cells were transfected with pre-miR-212 or treated with 
GL21.T, GL21.Tscr-miR212, GL21.T-miR212 for 48 hours 
and, then, incubated for 24 hours with TRAIL. The cells were 
washed in PBS, resuspended in binding buffer 10×, and 
labeled with Annexin V-FITC and propidium iodide accord-
ing to the manufacturer’s protocol. After incubation at room 
temperature for 15 minutes in the dark, cells were analyzed 
with a BD AccuriTM C6 Flow cytometry (BD Biosciences). To 
calculate the percent of apoptotic cells, the gate was placed 
on annexin V-positive, PI-negative cells, and thus double pos-
itive cells were excluded from the analysis.
Supplementary material
Figure S1. GL21.T-miR340 characterization.
Figure S2. Internalization of the GL21.T-miR212 conjugate 
in MCF7 exogenously expressing Axl.
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